<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id><journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id><journal-title-group><journal-title>Einstein</journal-title></journal-title-group><issn pub-type="ppub">1679-4508</issn><issn pub-type="epub">2317-6385</issn><publisher><publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25628188</article-id><article-id pub-id-type="pmc">4879903</article-id><article-id pub-id-type="publisher-id">S1679-45082014AO3095</article-id><article-id pub-id-type="doi">10.1590/S1679-45082014AO3095</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rebello</surname><given-names>Celso Moura</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Precioso</surname><given-names>Alexander Roberto</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mascaretti</surname><given-names>Renata Suman</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><collab>Grupo Colaborativo do Estudo Brasileiro Multic&#x000ea;ntrico de Surfactante</collab><xref ref-type="author-notes" rid="fn1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>
Hospital Israelita Albert Einstein, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff2"><label>2</label>
Instituto da Crian&#x000e7;a, Hospital das Cl&#x000ed;nicas, Faculdade de Medicina, Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff3"><label>3</label>
Maternidade Pro Matre Paulista, S&#x000e3;o Paulo, SP, Brazil.</aff><author-notes><corresp> Corresponding author: Celso Moura Rebello &#x02013; Avenida Albert Einstein, 627/701 &#x02013; Morumbi &#x02013; Zip code: 05652-900 &#x02013; S&#x000e3;o Paulo, SP, Brasil &#x02013; Phone: (55 11) 2151-2738 &#x02013; E-mail:
<email>celsomr@einstein.br</email></corresp><fn fn-type="con" id="fn1"><label>*</label><p>COLLABORATORS</p><p><bold>Hospital Sofia Feldman (MG), </bold>Carmen Maria Wurtz, Tatiana Coelho Lopes e Maria Aparecida de Castro Batista;<bold>Hospital Santa Isabel (SE), </bold>Carline Rabelo e Andrea Andrade Carvalho;<bold>Faculdade de Medicina de Botucatu da Universidade Estadual Paulista &#x0201c;J&#x000fa;lio de Mesquita Filho&#x0201d; &#x02212; UNESP (SP), </bold>Ligia M. S. Souza Rugolo e Jo&#x000e3;o Cesar Lyra;<bold>Hospital Maternidade Carmela Dutra (RJ), </bold>Giselle Iannarella Lacerda e Antonio Carlos de Almeida Melo;<bold>Universidade Estadual de Campinas &#x02013; UNICAMP (SP), </bold>S&#x000e9;rgio Tadeu Marba e Maria Aparecida M. S. Mezacapa;<bold>Hospital Geral de Bonsucesso (RJ), </bold>Daniela P. L. Peyneau e Fl&#x000e1;via Gon&#x000e7;alves Coelho Souza Oliveira;<bold>Maternidade Escola de Vila Nova Cachoeirinha (SP), </bold>Pedro Alexandre F. Brevel e Claudia Tanuri;<bold>Hospital Universit&#x000e1;rio &#x02013; Unidade Materno Infantil (MA), </bold>Fernando Lamy Filho e Vanda Maria Ferreira Sim&#x000f5;es;<bold>Hospital Regional de Taguatinga (Bras&#x000ed;lia), </bold>Rita de Cassia Werneck Ejima e Mariangela de Freitas Molina Pelicano;<bold>Maternidade Hildete Falc&#x000e3;o Batista (SE), </bold>Carline Rabelo e Maria Alexsandra S. Menezes;<bold>Hospital Universit&#x000e1;rio da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP), </bold>Maria Tereza Zulini da Costa e Ana Cl&#x000e1;udia C. Soares;<bold>Instituto Materno-Infantil (PE), </bold>Taciana Duque de Braga e Jucille Meneses;<bold>Hospital das Cl&#x000ed;nicas da Faculdade de Medicina de Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP), </bold>Francisco Eul&#x000f3;gio Martinez, Marisa M. Mussi-Pinhata e Walusa Assada Gon&#x000e7;alves Ferri;<bold>Hospital F&#x000ea;mina (RS), </bold>Lauro Luis Hagemann;<bold>Instituto da Crian&#x000e7;a do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP), </bold>Cl&#x000e9;a Rodrigues Leone e Marta M. G. B. Mataloun, Edna Maria de A. Diniz e Maria Esther J. R. Ceccon;<bold>Hospital J&#x000fa;lia Kibstchek (MG), </bold>Jos&#x000e9; Augusto Almeida Barbosa e Luciana Araujo Oliveira Cunha;<bold>Hospital Maternidade Oswaldo de Nazareth (RJ), </bold>Arnaldo Costa Bueno e Patricia Campanha;<bold>Hospital Alvorada (RS), </bold>Lauro Luis Hagemann e Claudio Grillo Moreira;<bold>Hospital de Cl&#x000ed;nicas de Minas Gerais (MG), </bold>Maria C&#x000e2;ndida V. B. Viana e Maria Albertina S. Rego;<bold>Faculdade de Sa&#x000fa;de P&#x000fa;blica da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP) Departamento de Epidemiologia: </bold>Maria Regina Alves Cardoso, Luiz Antonio V. D&#x000b4;Angelo e Patr&#x000ed;cia E. Braga</p></fn><fn fn-type="conflict"><p>Conflict of interest: none.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2014</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2014</year></pub-date><volume>12</volume><issue>4</issue><fpage>397</fpage><lpage>404</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>6</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p></license></permissions><abstract><sec><title>Objective</title><p> To compare the efficacy and safety of a new porcine-derived pulmonary surfactant developed by <italic>Instituto Butantan</italic> with those of animal-derived surfactants commercially available in Brazil, regarding neonatal mortality and the major complications of prematurity in preterm newborns with birth weight up to 1500g and diagnosed with respiratory distress syndrome.</p></sec><sec><title>Methods</title><p> Neonates diagnosed with respiratory distress syndrome were randomized to receive either Butantan surfactant (Butantan group) or one of the following surfactants: Survanta<sup>&#x000ae;</sup> or Curosurf<sup>&#x000ae;</sup>. Newborns receiving Survanta<sup>&#x000ae;</sup> or Curosurf<sup>&#x000ae;</sup> comprised the control group. The main outcome measures were mortality rates at 72 hours and at 28 days of life; the typical complications of prematurity as evaluated on the 28th day of life were defined as secundary outcomes.</p></sec><sec><title>Results</title><p> No differences were observed between the Butantan (n=154) and control (n=173) groups in relation to birth weight, gestational age, sex, and prenatal use of corticosteroids, or in mortality rates both at 72 hours (14.19% <italic>versus</italic> 14.12%; p=0.98) and at 28 days (39.86% <italic>versus</italic> 33.33%; p=0.24) of life. Higher 1- and 5-minute Apgar scores were observed among control group newborns. No differences were observed as regards the secondary outcomes, except for greater need for supplemental oxygen and a higher incidence of interstitial pulmonary emphysema in the Butantan group.</p></sec><sec><title>Conclusion</title><p> The mortality rates at 72 hours and 28 days of life and the incidence of major complications of prematurity were comparable to those found with the animal-derived surfactants commercially available in Brazil, showing the efficacy and safety of the new surfactant in the treatment of respiratory distress syndrome in newborns.</p></sec></abstract><kwd-group><kwd>Pulmonary surfactants/therapeutic use</kwd><kwd>Newborn, very low birth weight</kwd><kwd>Newborn</kwd><kwd>Preterm</kwd><kwd>Respiratory distress syndrome, newborn/drug therapy</kwd></kwd-group><counts><fig-count count="4"/><table-count count="10"/><equation-count count="0"/><ref-count count="26"/><page-count count="8"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>The neonatal respiratory distress syndrome (RDS) is primarily caused by a qualitative and quantitative surfactant deficiency at birth. Avery and Mead are responsible for the pioneering studies relating surfactant deficiency to this condition.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p><p>The first experimental study demonstrating the benefitial effect of surfactant replacement was conducted in the early 1970&#x02019;s by Enhornig and Robertson,<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> by means of the instillation of a natural surfactant, obtained from adult rabbits lungs, into the trachea of preterm rabbits. Subsequent studies have been conducted both to prove the efficacy of surfactants and to improve their extraction and purification. Some of the pioneers in clinical studies were Fujiwara et al.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> who proved, in a non-controlled study, improved oxygenation after surfactante administration in ten preterm newborns.</p><p>In the early 1990&#x02019;s, surfactants started to be routinely used in several neonatal intensive care centers. Since then, the &#x0201c;optimal surfactant&#x0201d; &#x02013; characterized by proven efficacy, safety, good resistance to inactivation by plasma proteins, and low cost, has been sought for routine use. The following functions are attributed to surfactants: preventing alveolar collapse at the end of expiration; secondarily decreasing alveolar edema; and showing actions related to immunity.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p><p>Exogenous surfactant therapy allowed a reduction in neonatal mortality rates among extremely preterm newborns, with an impact also on infant mortality rates in developed countries. A limitation for its large-scale use in preterm infants as well as in older children and adults is its high cost. Thus, aiming at attenuating this problem nationwide, <italic>Instituto Butantan</italic>&#x02013; located in the city of S&#x000e3;o Paulo (State of S&#x000e3;o Paulo), developed a new method of extraction and purification of a natural porcine-derived surfactant, and obtained a new product with a reduced production cost in relation to imported products.<sup>(<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup>
</p><p>This new process was based on maceration of suine lungs followed by organic extraction coupled to adsortion in diethylaminoethyl cellulose (DEAE-C). This technology has the advantage of reducing the costs of production not only for not using large industrial-scale refrigerated ultracentrifuges, but also for reusing the reagents used in the different stages of extraction. Its chemical composition is quite similar to that of other animal-derived surfactants, with its lipid content represented by phosphatidylcholine (76%), phosphatidylethanolamine (6 to 8%), phosphatidylglycerol (6%), phosphatidylinositol (6%), and sphingomyelin (4 to 6%), in addition to surfactant proteins B and C (5.6%).<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> The <italic>in vivo</italic> efficacy of this product was proven using an experimental RDS model.<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup> In view of the theoretical risk of immunogenicity to the proteins present in the pulmonary surfactant,<sup>(<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>)</sup> the immune response to exposure to a new product was studied, and it was demonstrated, in an animal model, that the surfactant produced by <italic>Instituto Butantan</italic> was not associated with the occurence of clinical manifestations that could preclude its use in preterm newborns with RDS.<sup>(<xref rid="B10" ref-type="bibr">10</xref>)</sup>
</p><p>The new surfactant was also used for the treatment of meconium aspiration syndrome in an animal model.<sup>(<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>)</sup> The results of these studies demonstrated that the animals treated with the surfactant produced by <italic>Instituto Butantan</italic> showed significant improvement of their pulmonary mechanics, pulmonary volumes, and histopathological patterns of alveolar aeration.<sup>(<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>)</sup> Based on these studies, we hypothesized that the surfactant produced by <italic>Instituto Butantan</italic> is as efficient and safe as the surfactants commercially available in Brazil for the treatment of neonatal RDS.</p></sec><sec><title>OBJECTIVE</title><p>To evaluate the efficacy and safety of a new porcine-derived pulmonary surfactant developed by <italic>Instituto Butantan</italic> for the treatment of neonatal respiratory distress syndrome, in comparison to those of animal-derived surfactants available in the country, particularly in relation to neonatal mortality and the incidence of pulmonary hemorrhage and pneumothorax.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study population</title><p>We conducted a multicenter, prospective, randomized study including 19 neonatal intensive care units distributed in the States of S&#x000e3;o Paulo (6 centers), Rio de Janeiro (3 centers), Minas Gerais (3 centers), Sergipe (2 centers), Rio Grande do Sul (2 centers), Pernambuco (1 center), Distrito Federal (1 center), and Maranh&#x000e3;o (1 center), from April 2005 to August 2007. Pregnant women at a high risk for preterm delivery (more than 24 weeks gestation and birth weight estimated at between 501 and 1,500g) were invited to participate in the study. If the inclusion criteria were met and the written informed consent was given, the newborn was considered eligible for randomization.</p><p>The inclusion criteria were: preterm neoneonates born in the study centers; with birth weight between 501 and 1,500g; postnatal age &#x02264;24 hours of life; undergoing mechanical ventilation; with an arterial oxygen pressure and inspired oxygen fraction ratio (PaO<sub>2</sub>/FiO<sub>2</sub>) &#x02264;175; clinically and radiologically diagnosed with RDS; and written informed consent given by parents or guardians.</p><p>The exclusion criteria were: previous treatment with another type of surfactant; newborn with major congenital malformations or previously diagnosed chromosomic abnormalities that could pose risk of death; persistent physiological instability including hypotension, bradycardia, seizures, unresolved pneumothorax, or pneumomediastinum; diagnosis of congenital infection or chorioamnionitis at birth.</p><p>An independent Patient Safety and Data Committee was formed for external study monitoring.</p><p>The study was approved by the Research Ethics Committees of all participating units, as well as by the National Research Ethics Commission (CONEP), under register CEP: 292/02, process number: 25000.D02529/2003-40, CONEP opinion: 620/2003.</p></sec><sec><title>Randomization and formation of the study groups</title><p>The animal-derived surfactants available in the country are Survanta<sup>&#x000ae;</sup> (Abbott Laboratories, Ohio, USA) and Curosurf<sup>&#x000ae;</sup><italic>(Chiesi Farmaceutici, </italic>Parma, Italy<italic>).</italic>The newborns were randomized to receive either the Butantan surfactant, comprising the Butantan group, or the commercial surfactant routinely used in the participating institution (Survanta<sup>&#x000ae;</sup> or Curosurf<sup>&#x000ae;</sup>), comprising the control group. Randomization was stratified separately according to the birth weight range (501-750g, 751-1,000g, and 1,001-1,500g) and to each participating study center.</p><p>The patients were randomized using blocks of four, thus allowing six draw combinations (AABB; ABAB; ABBA; BABA; BAAB and BBAA). Thus, each number drawn by lot corresponded to four children. This method has two advantages: it allows that, at every four newborns included in the study, there is always the same number of participants receiving treatment A or B; and it makes it difficult to predict the treatment to be administered to the next child included in the study, especially when performed separately for each stratum. One-digit numbers were repeatedly drawn by lot until the sample size required for each stratum was obtained.</p><p>The randomization process was performed by professionals from the Department of Epidemiology of the Public Health College,<italic>Universidade de S&#x000e3;o Paulo</italic>. The treatment assigned by randomization was noted down in a sealed opaque envelope. To ensure that the surfactant used in each treatment was not identified, the envelope was opened, the medication prepared, and surfactant was delivered in a sealed syringe to the team directly in charge of drug administration by persons not involved in the study (support pharmacist or nurse). All surfactants were kept at a temperature of approximately 4&#x000b0;C. The physicians in charge of the newborns remained blind to the type of surfactant used in each treatment until study completion.</p></sec><sec><title>Treatment strategy and post-treatment controls</title><p>A 100mg dose of phospholipids/kg was used for all newborns, in all treatments. Prior to administration, suctioning was performed only if necessary. After treatment, suctioning was performed again, observing a minimum 1-hour interval between administration and suctioning, or anytime if endotracheal tube obstruction was suspected. Treatment was given if the newborns did not present with physiological instability (presence of hypotension, bradycardia, seizure, unresolved pneumothorax, or pneumomediastinum), with the administration of a single dose, via endotracheal tube, at a constant speed, avoiding medication reflux. In each participating center, the treatment provided to newborns of the two study groups was identical.</p><p>Each newborn could receive two adittional surfactant doses at most, and the retreatment criterium was established when the PaO<sub>2</sub>/FiO<sub>2 </sub>ratio was &#x02264;175, without any other cause that could explain worsening of the respiratory function (for instance: pneumothorax and pulmonary hypertension). Retreament was performed after a minimum period of 6 hours following the previous dose and up to a maxium limit of 48 hours of life, using the same dose and administration technique.</p><p>Blood samples were drawn for arterial blood gas immediately before and 1 and 6 hours after administration of the first surfactant dose, for the calculation of the oxygenation index (OI), using the formula OI=(MAP x FiO<sub>2</sub>)/PaO<sub>2</sub> x 100, where MAP corresponds to the mean airway pressure. The ventilator settings were noted down immediately before and at 1, 6, 12, 18, 24, 30, 36, 42 and 48 hours after treatment, for the calculation of MAP values for each study group.</p></sec><sec><title>Definition of primary outcome measures</title><p>The primary outcome measures for this study were mortality at 72 hours and 28 days of life. The secondary outcome measures included complications typically associated with prematurity and mechanical ventilation.</p></sec></sec><sec><title>Statistical analysis</title><p>Continuous variables were analyzed using the Student&#x02019;s t or Mann-Whitney test, as appropriate. Qualitative variables were analyzed using the &#x003c7;<sup>2</sup> or Fischer&#x02019;s exact test, as appropriate. The sample size calculated to detect an increase in overall mortality from 23.0% to 33.0%, as was observed in the 41 Brazilian maternity hospitals participating in the Analysis and Intervention Project for the Improvement of Neonatal Care in Brazil, from 2009 to 2011, considering a significance level of 0.05 and a power of test of 0.8, was 316 newborns. The significance level was set at p&#x02264;0.05. The Stata &#x02013; Data Analysis and Statistical Software version 10.0 (StataCorp, USA) was used for data analysis.</p></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 1,797 very-low-birth-weight newborns were enrolled during the study period; 397 of them were randomized (<xref ref-type="fig" rid="f01">Figure 1</xref>). Of these, 70 newborns were excluded for: not meeting all the inclusion criteria; retreatment after more than 48 hours of life; newborn randomized, but not treated with surfactant; presence of chorioamnionitis; administration of more than three surfactant doses; breach of confidentiality on the surfactant to be administered; failure to follow the surfactant randomization; diagnosis of major malformation; birth outside the participating institution; clinical center excluded from the study; incomplete data recording; lack of written informed consent; lack of pre-treatment blood gas; hemodinamically unstable newborn; data recorded only after the second surfactant dose; newborn randomized, but not on mechanical ventilation; and lack of surfactant in the institution after administration of the second surfactant dose. Of the remaining 327 newborns, 154 were randomized to the Butantan group, and 173 to the control group (<xref ref-type="fig" rid="f01">Figure 1</xref>). The 1,400 non-randomized newbords did not fulfill all inclusion criteria. Main peri and postnatal demographic characteristcs of 327 newborns are showed in <xref ref-type="table" rid="t1">table 1</xref>. The mean birth weight (990&#x000b1;245g <italic>versus</italic> 996&#x000b1;235g) and gestational age (28.0&#x000b1;2.1 weeks <italic>versus</italic> 28.1&#x000b1;2.2 weeks) were similar for the control and Butantan groups, respectively. No differences were observed regarding sex, prenatal use of corticosteroid, mode of delivery, and classification according to weight and gestational age. Higher 1- and 5-minute Apgar scores were observed among newborns of the control group. The birth weight of approximately half of the children randomized to both groups was between 1,000 and 1,500g.</p><p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Patient selection flow chart</title></caption><graphic xlink:href="1679-4508-eins-12-4-0397-gf01"/></fig>
</p><p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Peri- and postnatal characteristics of the 327 newborns studied</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Control group (n=173)</th><th rowspan="1" colspan="1">Butantan group (n=154)</th><th rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Birth weight, g</td><td align="center" rowspan="1" colspan="1">990.65&#x000b1;245.70</td><td align="center" rowspan="1" colspan="1">996.01&#x000b1;235.84</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">Gestational age, weeks</td><td align="center" rowspan="1" colspan="1">28.03&#x000b1;2.07</td><td align="center" rowspan="1" colspan="1">28.14&#x000b1;2.16</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td rowspan="1" colspan="1">Sex, n (%)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">86 (49.71)</td><td align="center" rowspan="1" colspan="1">84 (54.55)</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">87 (50.29)</td><td align="center" rowspan="1" colspan="1">70 (45.45)</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td rowspan="1" colspan="1">Prenatal corticosteroid, n (%)</td><td align="center" rowspan="1" colspan="1">94 (54.34)</td><td align="center" rowspan="1" colspan="1">79 (51.30)</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td rowspan="1" colspan="1">Vaginal birth, n (%)</td><td align="center" rowspan="1" colspan="1">66 (38.15)</td><td align="center" rowspan="1" colspan="1">61 (39.66)</td><td align="center" rowspan="1" colspan="1">0.79</td></tr><tr><td rowspan="1" colspan="1">C-section birth, n (%)</td><td align="center" rowspan="1" colspan="1">107 (61.85)</td><td align="center" rowspan="1" colspan="1">93 (60.93)</td><td align="center" rowspan="1" colspan="1">0.79</td></tr><tr><td rowspan="1" colspan="1">1&#x02019; Apgar</td><td align="center" rowspan="1" colspan="1">5.2&#x000b1;2.4</td><td align="center" rowspan="1" colspan="1">4.5&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">0.006</td></tr><tr><td rowspan="1" colspan="1">5&#x02019; Apgar</td><td align="center" rowspan="1" colspan="1">7.9&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">7.4&#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">AGI, n (%)</td><td align="center" rowspan="1" colspan="1">125 (72.25 )</td><td align="center" rowspan="1" colspan="1">121 (78.57)</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">SGA, n (%)</td><td align="center" rowspan="1" colspan="1">48 (27.75)</td><td align="center" rowspan="1" colspan="1">33 (21.43)</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">LGA, n (%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">BW &#x0003c;750g, n (%)</td><td align="center" rowspan="1" colspan="1">32 (18.5)</td><td align="center" rowspan="1" colspan="1">23 (14.9)</td><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td rowspan="1" colspan="1">BW &#x02265;750g and &#x0003c;1,000g, n (%)</td><td align="center" rowspan="1" colspan="1">61 (35.26)</td><td align="center" rowspan="1" colspan="1">57 (37.01)</td><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td rowspan="1" colspan="1">BW &#x02265;1,000g and &#x0003c;1,500g, n (%)</td><td align="center" rowspan="1" colspan="1">80 (46.24)</td><td align="center" rowspan="1" colspan="1">74 (48.05)</td><td align="center" rowspan="1" colspan="1">0.69</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BW, Apagar score, and gestational age values are expressed as mean &#x000b1; standard deviation. Continuous variables were analyzed using the Student&#x02019;s t or Mann-Whitney test, as appropriate. Qualitative variables were analyzed using the &#x003c7;<sup>2</sup> or Fischer&#x02019;s exact test, as appropriate. AGA: appropriate for gestational age; SGA: small for gestational age; LGA: large for gestational age; BW: birth weight.</p></fn></table-wrap-foot></table-wrap>
</p><p>Butantan group newborns required more surfactant doses (mean &#x000b1; standard deviation) in comparison to those of the control group (2.0&#x000b1;0.8
<italic>versus</italic>
1.5&#x000b1;0.7, respectively; p&#x0003c;0,001). No difference was found between the two groups analyzed in relation to the moment (hours of life) at which the first surfactant dose was administered: control group, at 5.35 hours (median), and Butantan group, at 4,87 hours (median) (p=0,30).</p><sec><title>Primary outcome measures</title><p>No diferences were observed in relation to mortality between the Butantan and control groups, both at 72 hours (14.19%<italic>versus </italic>14.12%; p=0.98) and at 28 days of life (39.86%<italic>versus</italic>33.33%; p=0.24). Also, no differences were observed between the groups in relation to mortality, when analyzed by birth weight range, including birth weight &#x0003c;750g; birth weight between 750 and 999g; and birth weight between 1,000 and 1,499g (<xref ref-type="table" rid="t2">Tables 2</xref>
and
<xref ref-type="table" rid="t3">3</xref>).</p><p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Overall mortality and by birth weight range within the first 72 hours after the first surfactant dose</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Control group n (%)</th><th rowspan="1" colspan="1">Butantan group n (%)</th><th rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Overall mortality</td><td align="center" rowspan="1" colspan="1">24 (14.12)</td><td align="center" rowspan="1" colspan="1">22 (14.19 )</td><td align="center" rowspan="1" colspan="1">0.98</td></tr><tr><td rowspan="1" colspan="1">BW &#x0003c;750g (n=55)</td><td align="center" rowspan="1" colspan="1">11 (35.48 )</td><td align="center" rowspan="1" colspan="1">10 (39.13 )</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td rowspan="1" colspan="1">BW &#x02265;750g and &#x0003c;1,000g (n=115)</td><td align="center" rowspan="1" colspan="1">8 (13.56 )</td><td align="center" rowspan="1" colspan="1">8 (14.29 )</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">BW &#x02265;1,000g and &#x0003c;1,500g (n=151)</td><td align="center" rowspan="1" colspan="1">5 (6.36 )</td><td align="center" rowspan="1" colspan="1">4 (5.48 )</td><td align="center" rowspan="1" colspan="1">1.0</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>Continuous variables were analyzed using the Student&#x02019;s t or Mann-Whitney test, as appropriate. Qualitative variables were analyzed using the &#x003c7;<sup>2</sup> or Fischer&#x02019;s exact test, as appropriate. BW: birth weight.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Overall mortality and by birth weight range on the 28th day of life</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Secondary variables</th><th rowspan="1" colspan="1">Control group n (%)</th><th rowspan="1" colspan="1">Butantan group n (%)</th><th rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Overall mortality</td><td align="center" rowspan="1" colspan="1">55 (33.33)</td><td align="center" rowspan="1" colspan="1">57 (39.86)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td rowspan="1" colspan="1">BW &#x0003c;750g (n=53)</td><td align="center" rowspan="1" colspan="1">21 (67.74)</td><td align="center" rowspan="1" colspan="1">15 (68.18)</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td rowspan="1" colspan="1">BW &#x02265;750g and &#x0003c;1,000g (n=109)</td><td align="center" rowspan="1" colspan="1">23 (39.66)</td><td align="center" rowspan="1" colspan="1">26 (50.98)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td rowspan="1" colspan="1">BW &#x02265;1,000g and &#x0003c;1,500g (n=146)</td><td align="center" rowspan="1" colspan="1">11 (14.47)</td><td align="center" rowspan="1" colspan="1">16 (22.86)</td><td align="center" rowspan="1" colspan="1">0.19</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>Continuous variables were analyzed using the Student&#x02019;s t or Mann-Whitney test, as appropriate. Qualitative variables were analyzed using the &#x003c7;<sup>2</sup> or Fischer&#x02019;s exact test, as appropriate. BW: birth weight.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Secondary outcome measures</title><p>No differences were observed among newborns of the control and Butantan groups as regards the secondary variables analyzed on the 28th day of life (<xref ref-type="table" rid="t4">Table 4</xref>), except for greater need for supplemental oxygen (45.28%<italic>versus</italic>57.04%; p=0.05), and higher frequency of the diagnosis of persistent ductus arteriosus (31.45%<italic>versus</italic>44.93%; p=0.02) and of interstitial pulmonary emphysema (7.64%<italic>versus</italic>17.04%; p=0.01) in Butantan group newborns. The frequency of pulmonary hemorrhage was similar in both groups (12.58%<italic>versus</italic>11.59%; p=0.80).</p><p>
<table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Frequency of secondary variables analysed on the 28th day of life</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Secondary variables</th><th rowspan="1" colspan="1">Control group n (%)</th><th rowspan="1" colspan="1">Butantan group n (%)</th><th rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Use of oxygen at 28 days</td><td align="center" rowspan="1" colspan="1">72 (45.28)</td><td align="center" rowspan="1" colspan="1">77 (57.04)</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td rowspan="1" colspan="1">Radiography consistent with BPD</td><td align="center" rowspan="1" colspan="1">52 (65.00)</td><td align="center" rowspan="1" colspan="1">57 (72.15)</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td rowspan="1" colspan="1">Intracranial hemorrhage (total)</td><td align="center" rowspan="1" colspan="1">39 (24.53)</td><td align="center" rowspan="1" colspan="1">43 (31.16)</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grade I</td><td align="center" rowspan="1" colspan="1">17 (43.59)</td><td align="center" rowspan="1" colspan="1">17 (39.53)</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grade II</td><td align="center" rowspan="1" colspan="1">5 (12.82)</td><td align="center" rowspan="1" colspan="1">7 (16.28)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grade III</td><td align="center" rowspan="1" colspan="1">10 (25.64)</td><td align="center" rowspan="1" colspan="1">10 (23.26)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grade IV</td><td align="center" rowspan="1" colspan="1">7 (17.95)</td><td align="center" rowspan="1" colspan="1">9 (20.93)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">PDA (n=297)</td><td align="center" rowspan="1" colspan="1">50 (31.45)</td><td align="center" rowspan="1" colspan="1">62 (44.93)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">Early sepsis (n=297)</td><td align="center" rowspan="1" colspan="1">58 (36.48)</td><td align="center" rowspan="1" colspan="1">50 (36.23)</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td rowspan="1" colspan="1">Late sepsis (n=293)</td><td align="center" rowspan="1" colspan="1">59 (37.58)</td><td align="center" rowspan="1" colspan="1">51 (37.50)</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td rowspan="1" colspan="1">Pulmonary hemorrhage (n=297)</td><td align="center" rowspan="1" colspan="1">20 (12.58)</td><td align="center" rowspan="1" colspan="1">16 (11.59)</td><td align="center" rowspan="1" colspan="1">0.80</td></tr><tr><td rowspan="1" colspan="1">Pneumothorax (n=297)</td><td align="center" rowspan="1" colspan="1">13 (8.18)</td><td align="center" rowspan="1" colspan="1">12 (8.70)</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td rowspan="1" colspan="1">Interstitial emphysema (n=292)</td><td align="center" rowspan="1" colspan="1">12 (7.64)</td><td align="center" rowspan="1" colspan="1">23(17.04)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">Necrotizing enterocolitis (n=297)</td><td align="center" rowspan="1" colspan="1">11 (6.92)</td><td align="center" rowspan="1" colspan="1">11 (7.97)</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td rowspan="1" colspan="1">Mechanical ventilation time (days)</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td rowspan="1" colspan="1">Total oxygen therapy time (days)</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">0.35</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>Continuous variables were analyzed using the Student&#x02019;s t or Mann-Whitney test, as appropriate. Qualitative variables were analyzed using the &#x003c7;<sup>2</sup> or Fischer&#x02019;s exact test, as appropriate. BPD: bronchopulmonary displasia; PDA: persistent ductus arteriosus.</p></fn></table-wrap-foot></table-wrap>
</p><p>Reductions in both OI (<xref ref-type="table" rid="t5">Table 5</xref>) and MAP (<xref ref-type="fig" rid="f02">Figure 2</xref>) values were observed in the two groups after treatment with exogenous surfactant. However, the magnitude of decrease was greater in the newborns treated with Survanta<sup>&#x000ae;</sup> or Curosurf<sup>&#x000ae;</sup>, in relation to those treated with the Butantan surfactant.</p><p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Mean airway pressure values, pre- and post-treatment, in both study groups</title></caption><graphic xlink:href="1679-4508-eins-12-4-0397-gf02"/></fig>
</p><p>
<table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Oxygenation index values prior to treatment and 1 and 6 hours after (values in percentiles)</title></caption><table frame="hsides" rules="groups"><colgroup width="8%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Percentile</th><th rowspan="2" colspan="1">p value</th><th colspan="2" style="font-weight:normal" rowspan="1">10
<hr/>
</th><th colspan="2" style="font-weight:normal" rowspan="1">25
<hr/>
</th><th colspan="2" style="font-weight:normal" rowspan="1">50
<hr/>
</th><th colspan="2" style="font-weight:normal" rowspan="1">75
<hr/>
</th><th colspan="2" style="font-weight:normal" rowspan="1">90
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Group</th><th rowspan="1" colspan="1">CG</th><th rowspan="1" colspan="1">BG</th><th rowspan="1" colspan="1">CG</th><th rowspan="1" colspan="1">BG</th><th rowspan="1" colspan="1">CG</th><th rowspan="1" colspan="1">BG</th><th rowspan="1" colspan="1">CG</th><th rowspan="1" colspan="1">BG</th><th rowspan="1" colspan="1">CG</th><th rowspan="1" colspan="1">BG</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Pre-treatment</td><td align="center" rowspan="1" colspan="1">0.92</td><td align="center" rowspan="1" colspan="1">5.4</td><td align="center" rowspan="1" colspan="1">5.4</td><td align="center" rowspan="1" colspan="1">7.2</td><td align="center" rowspan="1" colspan="1">6.7</td><td align="center" rowspan="1" colspan="1">10.7</td><td align="center" rowspan="1" colspan="1">10.9</td><td align="center" rowspan="1" colspan="1">16.2</td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">24.5</td><td align="center" rowspan="1" colspan="1">25.6</td></tr><tr><td rowspan="1" colspan="1">1 hour after</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">7.8</td><td align="center" rowspan="1" colspan="1">7.2</td><td align="center" rowspan="1" colspan="1">12.7</td><td align="center" rowspan="1" colspan="1">13.2</td><td align="center" rowspan="1" colspan="1">20.1</td></tr><tr><td rowspan="1" colspan="1">6 hours after</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">2.0</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1">10.1</td><td align="center" rowspan="1" colspan="1">12.0</td><td align="center" rowspan="1" colspan="1">19.3</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>Continuous variables were analyzed using the Student&#x02019;s t or Mann-Whitney test, as appropriate. Qualitative variables were analyzed using the &#x003c7;<sup>2</sup> or Fischer&#x02019;s exact test, as appropriate. CG: control group; BG: Butantan group. Values expressed in percentiles.</p></fn></table-wrap-foot></table-wrap>
</p><p>In relation to the complications observed during surfactant administration, we observed that less children of the Butantan group showed bradycardia in relation to those of the control group (8.3%<italic>versus </italic>36.7%; p=0.002); both groups showed a similar incidence of surfactant reflux up the endotracheal tube (83.3%<italic>versus</italic>76.7%; p=0.470).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The main objective of this multicenter study was to verify the efficacy and safety of a new surfactant manufactured by
<italic>Instituto Butantan</italic>
in relation to similar products commercially available in Brazil. Mortality rates at 72 hours and on the 28th day of life were similar to those observed with the use of two animal-derived surfactants used in our setting. These observations show that the major benefit of using exogenous surfactants for the treatment of newborns with RDS,
<italic>i.e.</italic>
, mortality reduction, was obtained. This is important if we consider that, in several public maternity hospitals in our country, exogenous surfactant is not routinely available for clinical use because of its high cost. Equally important is the finding of a similar rate of the main diseases related to prematurity in both study groups, including bronchopulmonary dysplasia, grades III and IV intracranial hemorrhage, and necrotizing enterocolitis. Although the Butantan group had had a lower 5-minute Apgar score (7.9&#x000b1;1.5
<italic>versus</italic>
7.4&#x000b1;1.7; p=0.006), the magnitude of the difference had no clinical significance.</p><p>Although the incidence of pneumothorax had been very similar in both study groups, children treated with the Butantan surfactant showed a higher incidence of pulmonary interstitial emphysema. Both groups showed a quite higher overall incidence of extrapulmonary air than that reported, both with the use of lucinactant (a synthetical surfactant awaiting Food and Drug Administration &#x02013; FDA approval) and of poractant alfa (9.2% and 7.3%, respectively).<sup>(<xref rid="B13" ref-type="bibr">13</xref>)</sup> Immediate response to surfactant therapy was more evident in the control group, as demonstrated by a more marked reduction in the mean airway pressure and better OI values after treatment. However, when the variations in these parameteres are analyzed in both study groups, we verify that they were not associated with clinical differences between the groups, and this is demonstrated by a similar mechanical ventilation time, total oxygen time, and need for supplemental oxygen at 28 days of life, in addition to a similar mortality rate at 72 hours and 28 days of life, and incidence of pulmonary hemorrhage and pneumothorax.</p><p>For approximately two decades, the international literature has been discussing about the best way to evaluate whether a surfactant works adequately and how the efficacy of two surfactants may be compared in the treatment of a determined respiratory disease. Based on the evidences published, it is admitted that the acute effects of surfactants on the lungs (as assessed by oxygenation parameters) do not clearly predict their efficacy, and are less important than their influence on mortality associated with respiratory failure.<sup>(<xref rid="B14" ref-type="bibr">14</xref>-<xref rid="B17" ref-type="bibr">17</xref>)</sup> The first evidence of this fact is in studies comparing animal-derived to synthetic surfactants, in which it is clear that the surfactant used has its function improved after exposure to the preterm lung and modification within the pneumocyte II, being further released to the alveoli.<sup>(<xref rid="B14" ref-type="bibr">14</xref>)</sup> Thus, the assessment of mortality assicated with respiratory failure is the most important parameter in the evaluation of the therapeutic efficacy of a surfactant, in comparison to the evaluation of oxygenation itself. The second evidence is shown with the use of exogenous surfactants in the treatment of meconium aspiration syndrome in newborns.<sup>(<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>)</sup> In this disease, the international literature shows that exogenous surfactante therapy improves oxygenation in the short term. However, despite oxygenation improvement, clinical studies do not confirm a mortality reduction in meconium aspiration syndrome with exogenous surfactant therapy; thus, the use of surfactant in this condition is controversial and lacks consensus.<sup>(<xref rid="B20" ref-type="bibr">20</xref>)</sup> This stresses the superiority of the assessment of mortality in the analysis of the therapeutic efficacy of surfactants, in relation to its other effects on oxygenation.</p><p>In addition to the analysis of efficacy, it is also necessary to evaluate the safety of this new drug on the short (moment of administration) and long term (events that may arise as a result of its use). In this study, the safety of both groups was analyzed at the moment of administration (bradycardia and surfactant reflux up the endotracheal tube) and as regards the occurence of possible adverse effects associated with surfactants. The results obtained showed that, during surfactant administration, there was a higher incidence of surfactant reflux up the endotracheal tube among newborns of the Butantan group, and of bradycardia after surfactant administration among newborns of the control group. In relation to the adverse effects associated with the use of surfactants, we point out the occurrence of pulmonary hemorrhage, which is described in the international literature as the most severe event associated with this therapy.<sup>(<xref rid="B21" ref-type="bibr">21</xref>)</sup> The results obtained in this study showed that the incidence of pulmonary hemorrhage was similar in both groups analyzed.</p><p>As regards the surfactant dose used in this study, a certain number of clinical and pharmacokinetic studies show that higher doses are more efficient.<sup>(<xref rid="B22" ref-type="bibr">22</xref>)</sup> The choice to use the 100mg/kg dose was based on the fact that, in RDS, serum-derived protein inhibitors and inflammatory mediators that inactivate the surfactant system accumulate progressively, and treatment made in the initial phase is effective with the 100mg/kg dose.<sup>(<xref rid="B23" ref-type="bibr">23</xref>)</sup>
</p><p>Several studies have been conducted to compare synthetic (with no protein in their composition) to natural (bovine- or porcine-derived) surfactants, with better results achieved by animal-derived in relation to synthetic surfactants. Corroborating our findings, comparisons between different animal-derived surfactants (with apoproteins B and C in their composition) did not show different results in relation to mortality and the main morbidities related to prematurity, including mechanical ventilation settings, incidence of pneumothorax, insterstitial emphysema, intracranial hemorrage, and persistent ductus arteriosus, when compared at the same treatment dose.<sup>(<xref rid="B14" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>),
<xref rid="B26" ref-type="bibr">26</xref>)</sup>
</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The new surfactant developed for the treatment of respiratory distress syndrome in newborns is efficient and safe, and this was demonstrated by a similar neonatal mortality rate and incidence of pulmonary hemorrhage and pneumothorax in both study groups.</p></sec></body><back><fn-group><fn fn-type="supplementary-material"><p>
<bold>Clinical trial register</bold>
(
<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>
): protocol ID: NCT02305160</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avery</surname><given-names>ME</given-names></name><name><surname>Mead</surname><given-names>J</given-names></name></person-group><article-title>Surface properties in relation to atelectasis and hialyne membrane disease</article-title><source>Am J Dis Child</source><year>1959</year><volume>97</volume><issue>5 Pt 1</issue><fpage>517</fpage><lpage>523</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enh&#x000f6;rning</surname><given-names>G</given-names></name><name><surname>Robertson</surname><given-names>B</given-names></name></person-group><article-title>Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant</article-title><source>Pediatrics</source><year>1972</year><volume>50</volume><issue>1</issue><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">4483194</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>T</given-names></name><name><surname>Maeta</surname><given-names>H</given-names></name><name><surname>Chida</surname><given-names>S</given-names></name><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Watabe</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name></person-group><article-title>Artificial surfactant therapy in hyaline membrane disease</article-title><source>Lancet</source><year>1980</year><volume>1</volume><issue>8159</issue><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">6101413</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebello</surname><given-names>CM</given-names></name></person-group><article-title>Multiple utilization of surfactant in neonatology</article-title><source>Curr Respir Med Rev</source><year>2012</year><volume>8</volume><issue>1</issue><fpage>18</fpage><lpage>27</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubrusly</surname><given-names>FS</given-names></name><name><surname>Netto</surname><given-names>SL</given-names></name><name><surname>Iourtov</surname><given-names>D</given-names></name><name><surname>Raw</surname><given-names>I</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>PS</given-names></name></person-group><article-title>A natural surfactant from pig lungs</article-title><source>Biotechnol Lett</source><year>2000</year><volume>22</volume><fpage>1251</fpage><lpage>1253</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cianciarullo</surname><given-names>AM</given-names></name><name><surname>Leme</surname><given-names>E</given-names></name><name><surname>Be&#x000e7;ak</surname><given-names>W</given-names></name><name><surname>Raw</surname><given-names>I</given-names></name><name><surname>Kubrusly</surname><given-names>F</given-names></name></person-group><article-title>Ultrastructural chemical reaction to detect saturated phospholipids of a natural surfactant from pig lungs</article-title><source>Biotechnol Lett</source><year>2001</year><volume>23</volume><fpage>1293</fpage><lpage>1296</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcas</surname><given-names>RM</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Proen&#x000e7;a</surname><given-names>RS</given-names></name><name><surname>Reyes</surname><given-names>AM</given-names></name><name><surname>Lyra</surname><given-names>JC</given-names></name><name><surname>Gibeli</surname><given-names>MA</given-names></name><etal>et al</etal></person-group><article-title>In Vivo Testing of a New Low-Cost Surfactant Compared to Survanta Using the Preterm Rabbit Model: Lung Mechanics and Morphometric Analysis</article-title><source>Pediat Res</source><year>2000</year><volume>47</volume><issue>4 Pt 2</issue><size units="pages">386a</size></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whisett</surname><given-names>JA</given-names></name><name><surname>Hull</surname><given-names>WM</given-names></name><name><surname>Luse</surname><given-names>S</given-names></name></person-group><article-title>Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with survanta, a modified bovine surfactant</article-title><source>Pediatrics</source><year>1991</year><volume>87</volume><issue>4</issue><fpage>505</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">2011428</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stryer</surname><given-names>DK</given-names></name><name><surname>Merrit</surname><given-names>TA</given-names></name><name><surname>Jameson</surname><given-names>LM</given-names></name><name><surname>Hallman</surname><given-names>M</given-names></name></person-group><article-title>Surfactant-anti-surfactant immune complexes in infants with respiratory distress syndrome</article-title><source>Am J Pathol</source><year>1986</year><volume>122</volume><issue>2</issue><fpage>353</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">3511728</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Precioso</surname><given-names>AR</given-names></name><name><surname>Sakae</surname><given-names>PP</given-names></name><name><surname>Mascaretti</surname><given-names>RS</given-names></name><name><surname>Kubrusly</surname><given-names>FS</given-names></name><name><surname>Gebara</surname><given-names>VC</given-names></name><name><surname>Iourtov</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Analysis of the immunogenicity and stability of a porcine pulmonary surfactant preparation administered in rabbits</article-title><source>Clinics</source><year>2006</year><volume>61</volume><issue>2</issue><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">16680333</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyra</surname><given-names>JC</given-names></name><name><surname>Mascaretti</surname><given-names>RS</given-names></name><name><surname>Precioso</surname><given-names>AR</given-names></name><name><surname>Chia</surname><given-names>CY</given-names></name><name><surname>Costa</surname><given-names>MT</given-names></name><name><surname>Okay</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Different doses of exogenous surfactant for treatment of meconium spiration syndrome in newborn rabbits</article-title><source>Rev Hosp Cl&#x000ed;n Fac Med Sao Paulo</source><year>2004</year><volume>59</volume><issue>3</issue><fpage>104</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">15286829</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyra</surname><given-names>JC</given-names></name><name><surname>Mascaretti</surname><given-names>RS</given-names></name><name><surname>Precioso</surname><given-names>AR</given-names></name><name><surname>Haddad</surname><given-names>LB</given-names></name><name><surname>Mauad</surname><given-names>T</given-names></name><name><surname>Rebello</surname><given-names>CM</given-names></name></person-group><article-title>Polyethylene glycol addition does not improve exogenous surfactant function in an experimental model of meconium aspiration syndrome</article-title><source>Exp Lung Res</source><year>2009</year><volume>35</volume><issue>1</issue><fpage>76</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">19191106</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>SK</given-names></name><name><surname>Masmonteil</surname><given-names>TL</given-names></name><name><surname>Soler</surname><given-names>AV</given-names></name><name><surname>Wiswell</surname><given-names>TE</given-names></name><name><surname>Gadzinowski</surname><given-names>J</given-names></name><name><surname>Hajdu</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome</article-title><source>Pediatrics</source><year>2005</year><volume>115</volume><issue>4</issue><fpage>1030</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">15805381</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soll</surname><given-names>RF</given-names></name><name><surname>Blanco</surname><given-names>F</given-names></name></person-group><article-title>Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>11</volume><size units="pages">CD001456</size></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>TP</given-names></name><name><surname>Sinkin</surname><given-names>RA</given-names></name></person-group><article-title>Surfactant replacement therapy</article-title><source>Chest</source><year>2007</year><volume>131</volume><issue>5</issue><fpage>1577</fpage><lpage>1582</lpage><pub-id pub-id-type="pmid">17494810</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>HL</given-names></name></person-group><article-title>Recent clinical trials of surfactant treatment for neonates</article-title><source>Biol Neonate</source><year>2006</year><volume>89</volume><issue>4</issue><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">16770072</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engle</surname><given-names>WA</given-names></name><collab>American Academy of Pediatrics Committee on Fetus and Newborn</collab></person-group><article-title>Surfactant-replacement therapy for respiratory distress in the preterm and term neonate</article-title><source>Pediatrics</source><year>2008</year><volume>121</volume><issue>2</issue><fpage>419</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">18245434</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotze</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>BR</given-names></name><name><surname>Bulas</surname><given-names>DI</given-names></name><name><surname>Zola</surname><given-names>EM</given-names></name><name><surname>Shalwitz</surname><given-names>RA</given-names></name><name><surname>Gunkel</surname><given-names>JR</given-names></name></person-group><article-title>Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure</article-title><source>J Pediatr</source><year>1998</year><volume>132</volume><issue>1</issue><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">9469998</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Findlay</surname><given-names>RD</given-names></name><name><surname>Taeusch</surname><given-names>HW</given-names></name><name><surname>Walther</surname><given-names>FJ</given-names></name></person-group><article-title>Surfactant replacement therapy for meconium aspiration syndrome</article-title><source>Pediatrics</source><year>1996</year><volume>97</volume><issue>1</issue><fpage>48</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">8545223</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mokra</surname><given-names>D</given-names></name><name><surname>Calkovska</surname><given-names>A</given-names></name></person-group><article-title>How to overcome surfactant dysfunction in meconium aspiration syndrome?</article-title><source>Respir Physiol Neurobiol</source><year>2013</year><volume>187</volume><issue>1</issue><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">23473924</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raju</surname><given-names>TN</given-names></name><name><surname>Langenberg</surname><given-names>P</given-names></name></person-group><article-title>Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis</article-title><source>J Pediatr</source><year>1993</year><volume>123</volume><issue>4</issue><fpage>603</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">8410518</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Speer</surname><given-names>CP</given-names></name><name><surname>Sweet</surname><given-names>DG</given-names></name></person-group><chapter-title>Surfactant replacement: present and future</chapter-title><person-group person-group-type="editor"><name><surname>Bancalari</surname><given-names>E</given-names></name></person-group><source>The newborn lung</source><edition>2nd</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Elsevier Saunders</publisher-name><year>2012</year><fpage>283</fpage><lpage>299</lpage></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speer</surname><given-names>CP</given-names></name><name><surname>Sweet</surname><given-names>DG</given-names></name><name><surname>Halliday</surname><given-names>HL</given-names></name></person-group><article-title>Surfactant therapy: past, present and future</article-title><source>Early Human Dev</source><year>2013</year><volume>89</volume><issue>Suupl 1</issue><comment>S1</comment><fpage>S22</fpage><lpage>S24</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chess</surname><given-names>P</given-names></name><name><surname>Finkelstein</surname><given-names>JN</given-names></name><name><surname>Holm</surname><given-names>BA</given-names></name><name><surname>Notter</surname><given-names>RH</given-names></name></person-group><chapter-title>Surfactant replacement therapy in lung injury</chapter-title><person-group person-group-type="editor"><name><surname>Notter</surname><given-names>RH</given-names></name><name><surname>Finkelstein</surname><given-names>JN</given-names></name><name><surname>Holm</surname><given-names>BA</given-names></name></person-group><source>Lung injury: mechanisms, pathophysiology, and therapy</source><publisher-loc>Boca Raton</publisher-loc><publisher-name>Taylor &#x00026; Francis</publisher-name><year>2005</year><fpage>617</fpage><lpage>663</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Schwan</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Holm</surname><given-names>BA</given-names></name><name><surname>Baatz</surname><given-names>JE</given-names></name><etal>et al</etal></person-group><article-title>Surface properties of sulfur- and ether-linked phosphonolipids with and without purified hydrophobic lung surfactant proteins</article-title><source>Chem Phys Lipids</source><year>2005</year><volume>137</volume><issue>1-2</issue><fpage>77</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16109391</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhyay</surname><given-names>A</given-names></name><name><surname>Lal</surname><given-names>P</given-names></name></person-group><article-title>Practical issues in surfactant replacement therapy in respiratory distress syndrome in newborns</article-title><source>J Neonatol</source><year>2011</year><volume>25</volume><issue>2</issue><fpage>91</fpage><lpage>97</lpage></element-citation></ref></ref-list></back><sub-article id="TRpt" article-type="translation" xml:lang="pt"><front-stub><article-categories><subj-group subj-group-type="heading"><subject>Artigo Original</subject></subj-group></article-categories><title-group><article-title>Ensaio cl&#x000ed;nico multic&#x000ea;ntrico duplo-cego randomizado com um novo surfactante de origem porcina em prematuros com s&#x000ed;ndrome do desconforto respirat&#x000f3;rio</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rebello</surname><given-names>Celso Moura</given-names></name><xref ref-type="aff" rid="aff1002"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Precioso</surname><given-names>Alexander Roberto</given-names></name><xref ref-type="aff" rid="aff2002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mascaretti</surname><given-names>Renata Suman</given-names></name><xref ref-type="aff" rid="aff3002"><sup>3</sup></xref></contrib><contrib contrib-type="author"><collab>Grupo Colaborativo do Estudo Brasileiro Multic&#x000ea;ntrico de Surfactante</collab><xref ref-type="author-notes" rid="fn2">*</xref></contrib></contrib-group><aff id="aff1002"><label>1</label>
Hospital Israelita Albert Einstein, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff2002"><label>2</label>
Instituto da Crian&#x000e7;a, Hospital das Cl&#x000ed;nicas, Faculdade de Medicina, Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brasil.</aff><aff id="aff3002"><label>3</label>
Maternidade Pro Matre Paulista, S&#x000e3;o Paulo, SP, Brasil.</aff><author-notes><corresp>Autor correspondente: Celso Moura Rebello &#x02013; Avenida Albert Einstein, 627/701 &#x02013; Morumbi &#x02013; CEP:05652-900 &#x02013; S&#x000e3;o Paulo, SP, Brasil &#x02013; Tel.: (11) 2151-2738 &#x02013; E-mail:
<email>celsomr@einstein.br</email></corresp><fn fn-type="conflict"><p>Conflito de interesse: n&#x000e3;o h&#x000e1;.</p></fn><fn id="fn2" fn-type="con"><label>*</label><p>COLABORADORES</p><p><bold>Hospital Sofia Feldman (MG),</bold>Carmen Maria Wurtz, Tatiana Coelho Lopes e Maria Aparecida de Castro Batista;<bold>Hospital Santa Isabel (SE),</bold>Carline Rabelo e Andrea Andrade Carvalho;<bold>Faculdade de Medicina de Botucatu da Universidade Estadual Paulista &#x0201c;J&#x000fa;lio</bold><bold>de Mesquita Filho&#x0201d; &#x02212; UNESP (SP),</bold>Ligia M. S. Souza Rugolo e Jo&#x000e3;o Cesar Lyra;<bold>Hospital Maternidade</bold><bold>Carmela Dutra (RJ),</bold>Giselle Iannarella Lacerda e Antonio Carlos de Almeida Melo;<bold>Universidade</bold><bold>Estadual de Campinas &#x02013; UNICAMP (SP),</bold>S&#x000e9;rgio Tadeu Marba e Maria Aparecida M. S. Mezacapa;<bold>Hospital Geral de Bonsucesso (RJ),</bold>Daniela P. L. Peyneau e Fl&#x000e1;via Gon&#x000e7;alves Coelho Souza Oliveira;<bold>Maternidade Escola de Vila Nova Cachoeirinha (SP),</bold>Pedro Alexandre F. Brevel e Claudia Tanuri;<bold>Hospital Universit&#x000e1;rio &#x02013; Unidade Materno Infantil (MA),</bold>Fernando Lamy Filho e Vanda Maria Ferreira Sim&#x000f5;es;<bold>Hospital Regional de Taguatinga (Bras&#x000ed;lia),</bold>Rita de Cassia Werneck Ejima e Mariangela de Freitas Molina Pelicano;<bold>Maternidade Hildete Falc&#x000e3;o Batista (SE),</bold>Carline Rabelo e Maria Alexsandra S. Menezes;<bold>Hospital Universit&#x000e1;rio da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP),</bold>Maria Tereza Zulini da Costa e Ana Cl&#x000e1;udia C. Soares;<bold>Instituto Materno-Infantil (PE),</bold>Taciana Duque de Braga e Jucille Meneses;<bold>Hospital das Cl&#x000ed;nicas da Faculdade de Medicina de Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP),</bold>Francisco Eul&#x000f3;gio Martinez, Marisa M. Mussi-Pinhata e Walusa Assada Gon&#x000e7;alves Ferri;<bold>Hospital F&#x000ea;mina (RS),</bold>Lauro Luis Hagemann;<bold>Instituto da Crian&#x000e7;a do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP),</bold>Cl&#x000e9;a Rodrigues Leone e Marta M. G. B. Mataloun, Edna Maria de A. Diniz e Maria Esther J. R. Ceccon;<bold>Hospital J&#x000fa;lia Kibstchek (MG),</bold>Jos&#x000e9; Augusto Almeida Barbosa e Luciana Araujo Oliveira Cunha;<bold>Hospital Maternidade Oswaldo de Nazareth (RJ),</bold>Arnaldo Costa Bueno e Patricia Campanha;<bold>Hospital Alvorada (RS),</bold>Lauro Luis Hagemann e Claudio Grillo Moreira;<bold>Hospital de Cl&#x000ed;nicas de Minas Gerais (MG),</bold>Maria C&#x000e2;ndida V. B. Viana e Maria Albertina S. Rego;<bold>Faculdade de Sa&#x000fa;de P&#x000fa;blica da Universidade de S&#x000e3;o Paulo &#x02212; USP (SP) Departamento de Epidemiologia:</bold>Maria Regina Alves Cardoso, Luiz Antonio V. D&#x000b4;Angelo e Patr&#x000ed;cia E. Braga.</p></fn></author-notes><abstract><sec><title>Objetivo</title><p>Comparar a efic&#x000e1;cia e a seguran&#x000e7;a de um novo surfactante pulmonar de origem porcina, desenvolvido pelo Instituto Butantan, com os surfactantes de origem animal dispon&#x000ed;veis no pa&#x000ed;s, em rela&#x000e7;&#x000e3;o &#x000e0; mortalidade neonatal e &#x000e0;s principais complica&#x000e7;&#x000f5;es da prematuridade, em prematuros com peso de nascimento at&#x000e9; 1500g e diagn&#x000f3;stico de s&#x000ed;ndrome do desconforto respirat&#x000f3;rio.</p></sec><sec><title>M&#x000e9;todos</title><p>Rec&#x000e9;m-nascidos com diagn&#x000f3;stico de s&#x000ed;ndrome do desconforto respirat&#x000f3;rio foram randomizados para receber surfactante Butantan (Grupo Butantan) ou um dos seguintes surfactantes: Survanta<sup>&#x000ae;</sup>ou Curosurf<sup>&#x000ae;</sup>. Os rec&#x000e9;m-nascidos que receberam Survanta<sup>&#x000ae;</sup>ou Curosurf<sup>&#x000ae;</sup>formaram o Grupo Controle. Foram definidas, como vari&#x000e1;veis prim&#x000e1;rias, as mortalidades com 72 horas e 28 dias de vida e, como vari&#x000e1;veis secund&#x000e1;rias, as principais complica&#x000e7;&#x000f5;es t&#x000ed;picas da prematuridade, avaliadas no 28<sup><underline>O</underline></sup>dia de vida.</p></sec><sec><title>Resultados</title><p>N&#x000e3;o foram observadas diferen&#x000e7;as em rela&#x000e7;&#x000e3;o ao peso de nascimento, idade gestacional, sexo e corticoide pr&#x000e9;-natal, assim como em rela&#x000e7;&#x000e3;o &#x000e0; mortalidade dos rec&#x000e9;m-nascidos dos Grupos Butantan (n=154) e Controle (n=173), tanto com 72 horas (14,19%
<italic>versus</italic> 14,12%; p=0,98) como em 28 dias de vida (39,86%
<italic>versus</italic> 33,33%; p=0,24). Foram observados maiores valores do boletim de Apgar de 1 e de 5 minutos entre os rec&#x000e9;m-nascidos do Grupo Controle. Os grupos n&#x000e3;o diferiram em rela&#x000e7;&#x000e3;o &#x000e0;s vari&#x000e1;veis secund&#x000e1;rias, exceto por uma maior necessidade de uso de oxig&#x000ea;nio e de enfisema pulmonar intersticial no Grupo Butantan.</p></sec><sec><title>Conclus&#x000e3;o</title><p>As taxas de mortalidade com 72 horas e 28 dias de vida, assim como a incid&#x000ea;ncia das principais complica&#x000e7;&#x000f5;es da prematuridade, foram compar&#x000e1;veis &#x000e0;quelas encontradas com os surfactantes de origem animal comercialmente dispon&#x000ed;veis no Brasil, mostrando a efic&#x000e1;cia e a seguran&#x000e7;a do novo surfactante no tratamento da s&#x000ed;ndrome do desconforto respirat&#x000f3;rio em rec&#x000e9;m-nascidos.</p></sec></abstract><kwd-group><kwd>Surfactantes pulmonares/uso terap&#x000ea;utico</kwd><kwd>Rec&#x000e9;m-nascido de muito baixo peso</kwd><kwd>Rec&#x000e9;m-nascido</kwd><kwd>Prematuro</kwd><kwd>S&#x000ed;ndrome do desconforto respirat&#x000f3;rio do rec&#x000e9;m-nascido/quimioterapia</kwd></kwd-group></front-stub><body><sec><title>INTRODU&#x000c7;&#x000c3;O</title><p>A s&#x000ed;ndrome do desconforto respirat&#x000f3;rio (SDR) neonatal &#x000e9; causada primariamente por uma defici&#x000ea;ncia qualitativa e quantitativa de surfactante ao nascimento, sendo Avery e Mead os respons&#x000e1;veis pelos primeiros estudos que relacionaram a defici&#x000ea;ncia de surfactante &#x000e0; essa doen&#x000e7;a.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup></p><p>O primeiro estudo experimental que demonstrou a a&#x000e7;&#x000e3;o ben&#x000e9;fica da reposi&#x000e7;&#x000e3;o de surfactante foi realizado no in&#x000ed;cio da d&#x000e9;cada de 1970 por Enhornig e Robertson,<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>por meio da instila&#x000e7;&#x000e3;o de surfactante natural obtido dos pulm&#x000f5;es de coelhos adultos na traqueia de coelhos prematuros. Trabalhos subsequentes foram realizados tanto para comprovar sua efic&#x000e1;cia quanto para aperfei&#x000e7;oar sua extra&#x000e7;&#x000e3;o e purifica&#x000e7;&#x000e3;o. Um dos pioneiros nos estudos cl&#x000ed;nicos foi Fujiwara et al.,<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>que comprovaram, em um estudo n&#x000e3;o controlado, a melhora da oxigena&#x000e7;&#x000e3;o ap&#x000f3;s a administra&#x000e7;&#x000e3;o do surfactante, em dez rec&#x000e9;m-nascidos prematuros.</p><p>No in&#x000ed;cio dos anos 1990, o surfactante passou a ser utilizado como rotina em v&#x000e1;rios centros de cuidados intensivos neonatais. Desde ent&#x000e3;o, tem-se procurado a obten&#x000e7;&#x000e3;o do &#x0201c;surfactante ideal&#x0201d; para o uso rotineiro, caracterizado por efic&#x000e1;cia comprovada, seguran&#x000e7;a, boa resist&#x000ea;ncia &#x000e0; inativa&#x000e7;&#x000e3;o por prote&#x000ed;nas plasm&#x000e1;ticas e baixo custo. Ao surfactante, s&#x000e3;o atribu&#x000ed;das as seguintes fun&#x000e7;&#x000f5;es: evitar o colabamento alveolar no final da expira&#x000e7;&#x000e3;o, diminuir secundariamente o edema alveolar e apresentar a&#x000e7;&#x000f5;es relacionadas &#x000e0; imunidade.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup></p><p>A terap&#x000ea;utica com o surfactante ex&#x000f3;geno permitiu uma redu&#x000e7;&#x000e3;o das taxas de mortalidade neonatal entre os prematuros extremos, com impacto inclusive sobre a mortalidade infantil nos pa&#x000ed;ses desenvolvidos. Uma limita&#x000e7;&#x000e3;o para seu uso em larga escala, em prematuros e tamb&#x000e9;m em crian&#x000e7;as maiores e adultos, &#x000e9; seu alto custo. Dessa forma, o Instituto Butantan, localizado na cidade de S&#x000e3;o Paulo (SP), visando atenuar esse problema a n&#x000ed;vel nacional, desenvolveu um novo m&#x000e9;todo de extra&#x000e7;&#x000e3;o e purifica&#x000e7;&#x000e3;o do surfactante natural de origem porcina, obtendo um novo produto, com custo de produ&#x000e7;&#x000e3;o reduzido em rela&#x000e7;&#x000e3;o aos produtos importados.<sup>(<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup></p><p>Esse novo processo se baseou na macera&#x000e7;&#x000e3;o de pulm&#x000e3;o de su&#x000ed;nos, seguida de extra&#x000e7;&#x000e3;o org&#x000e2;nica acoplada &#x000e0; adsors&#x000e3;o em dietilaminoetil celulose (DEAE-C). Essa tecnologia teve a vantagem de reduzir os custos de produ&#x000e7;&#x000e3;o, n&#x000e3;o apenas por n&#x000e3;o utilizar grandes ultracentr&#x000ed;fugas refrigeradas de escala industrial, mas tamb&#x000e9;m pelo reaproveitamento dos reagentes utilizados nas v&#x000e1;rias etapas da extra&#x000e7;&#x000e3;o. Sua composi&#x000e7;&#x000e3;o qu&#x000ed;mica &#x000e9; bastante semelhante &#x000e0; de outros surfactantes de origem animal, sendo o conte&#x000fa;do lip&#x000ed;dico representado pela fosfatidilcolina (76%), fosfatidiletanolamina (6 a 8%), fosfatidilglicerol (6%), fosfatidilinositol (6%) e esfingomielina (4 a 6%), al&#x000e9;m das prote&#x000ed;nas B e C do surfactante (5,6%).<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup>Esse produto teve sua efic&#x000e1;cia comprovada<italic>i</italic><italic>n vivo</italic>, utilizando-se um modelo experimental de SDR.<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup>Em vista do risco te&#x000f3;rico de imunogenicidade &#x000e0;s prote&#x000ed;nas presentes no surfactante pulmonar,<sup>(<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">8</xref>)</sup>a resposta imunol&#x000f3;gica &#x000e0; exposi&#x000e7;&#x000e3;o ao novo produto foi pesquisada, sendo demonstrado, em modelo animal, que o surfactante produzido pelo Instituto Butantan n&#x000e3;o esteve associado &#x000e0; ocorr&#x000ea;ncia de manifesta&#x000e7;&#x000f5;es cl&#x000ed;nicas que inviabilizassem seu uso em rec&#x000e9;m-nascidos prematuros com SDR.<sup>(<xref rid="B10" ref-type="bibr">10</xref>)</sup></p><p>O novo surfactante tamb&#x000e9;m foi utilizado para o tratamento da s&#x000ed;ndrome de aspira&#x000e7;&#x000e3;o meconial em modelo animal.<sup>(<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>)</sup>Os resultados desses estudos demonstraram que os animais tratados com o surfactante produzido pelo Instituto Butantan apresentaram melhora significativa da mec&#x000e2;nica pulmonar, dos volumes pulmonares e dos padr&#x000f5;es histopatol&#x000f3;gicos de aera&#x000e7;&#x000e3;o alveolar.<sup>(<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>)</sup>Com base nesses estudos, foi aventada a hip&#x000f3;tese de que o surfactante produzido pelo Instituto Butantan &#x000e9; t&#x000e3;o eficaz e seguro quanto os surfactantes dispon&#x000ed;veis comercialmente no Brasil para o tratamento da SDR neonatal.</p></sec><sec><title>OBJETIVO</title><p>Avaliar a efic&#x000e1;cia e seguran&#x000e7;a de um novo surfactante pulmonar de origem porcina, desenvolvido pelo Instituto Butantan, para o tratamento da s&#x000ed;ndrome do desconforto respirat&#x000f3;rio neonatal, quando comparado aos surfactantes de origem animal dispon&#x000ed;veis no pa&#x000ed;s, particularmente em rela&#x000e7;&#x000e3;o &#x000e0; mortalidade neonatal, &#x000e0; incid&#x000ea;ncia de hemorragia pulmonar e &#x000e0; de pneumot&#x000f3;rax.</p></sec><sec><title>M&#x000c9;TODOS</title><sec><title>Popula&#x000e7;&#x000e3;o do estudo</title><p>Foi realizado um estudo multic&#x000ea;ntrico, prospectivo, randomizado, incluindo 19 unidades de terapia intensiva neonatal distribu&#x000ed;das nos Estados de S&#x000e3;o Paulo (6 centros), Rio de Janeiro (3 centros), Minas Gerais (3 centros), Sergipe (2 centros), Rio Grande do Sul (2 centros), Pernambuco (1 centro), Distrito Federal (1 centro) e Maranh&#x000e3;o (1 centro), no per&#x000ed;odo de abril de 2005 a agosto de 2007. As gestantes com alto risco de parto prematuro (acima de 24 semanas de gesta&#x000e7;&#x000e3;o e peso de nascimento estimado entre 501 e 1.500g) foram abordadas em rela&#x000e7;&#x000e3;o &#x000e0; participa&#x000e7;&#x000e3;o no estudo. Se os crit&#x000e9;rios de inclus&#x000e3;o fossem atingidos e o consentimento livre e esclarecido fosse obtido, o rec&#x000e9;m-nascido era considerado eleg&#x000ed;vel para randomiza&#x000e7;&#x000e3;o.</p><p>Foram crit&#x000e9;rios de inclus&#x000e3;o: rec&#x000e9;m-nascidos prematuros nascidos nos centros envolvidos nesse estudo; com peso de nascimento entre 501 e 1.500g; idade p&#x000f3;s-natal &#x02264;24 horas de vida; em ventila&#x000e7;&#x000e3;o mec&#x000e2;nica; com rela&#x000e7;&#x000e3;o entre press&#x000e3;o arterial de oxig&#x000ea;nio e fra&#x000e7;&#x000e3;o inspirada de oxig&#x000ea;nio (PaO<sub>2</sub>/FiO<sub>2</sub>) &#x02264;175; diagn&#x000f3;stico cl&#x000ed;nico e radiol&#x000f3;gico de SDR; e consentimento livre e esclarecido assinado pelos pais ou respons&#x000e1;vel legal.</p><p>Os crit&#x000e9;rios de exclus&#x000e3;o foram: tratamento pr&#x000e9;vio com outro tipo de surfactante; rec&#x000e9;m-nascidos com malforma&#x000e7;&#x000f5;es cong&#x000ea;nitas maiores ou altera&#x000e7;&#x000f5;es cromoss&#x000f4;micas previamente diagnosticadas que acarretassem em risco de vida; instabilidade fisiol&#x000f3;gica persistente, incluindo hipotens&#x000e3;o, bradicardia, convuls&#x000e3;o, pneumot&#x000f3;rax n&#x000e3;o resolvido ou pneumomediastino; Diagn&#x000f3;stico de infe&#x000e7;&#x000e3;o cong&#x000ea;nita ou ovular ao nascimento.</p><p>Um Comit&#x000ea; de Dados e de Seguran&#x000e7;a do Paciente independente foi constitu&#x000ed;do com a finalidade de monitoriza&#x000e7;&#x000e3;o externa do estudo.</p><p>O estudo foi aprovado pelos Comit&#x000ea;s de &#x000c9;tica em Pesquisa de todas as unidades participantes, assim como pela Comiss&#x000e3;o Nacional de &#x000c9;tica em Pesquisa (CONEP), com registro CEP: 292/02, processo n&#x000fa;mero: 25000.D02529/2003-40, parecer CONEP: 620/2003.</p></sec><sec><title>Randomiza&#x000e7;&#x000e3;o e forma&#x000e7;&#x000e3;o dos grupos de estudo</title><p>Os surfactantes de origem animal dispon&#x000ed;veis no pa&#x000ed;s s&#x000e3;o o Survanta<sup>&#x000ae;</sup>(<italic>Abbott Laboratories,</italic> Ohio, Estados Unidos) e Curosurf<sup>&#x000ae;</sup>(<italic>Chiesi Farmaceutici</italic>, Parma, It&#x000e1;lia). Os rec&#x000e9;m-nascidos foram randomizados para receber o surfactante Butantan, constituindo o Grupo Butantan, ou o surfactante comercial de uso de rotina da institui&#x000e7;&#x000e3;o participante (Survanta<sup>&#x000ae;</sup>ou Curosurf<sup>&#x000ae;</sup>), constituindo, assim, o Grupo Controle. A randomiza&#x000e7;&#x000e3;o foi estratificada separadamente de acordo com a faixa de peso de nascimento (501-750g, 751-1.000g, e 1.001-1.500g) e com cada centro participante do estudo.</p><p>O m&#x000e9;todo utilizado para a randomiza&#x000e7;&#x000e3;o das crian&#x000e7;as foi o de blocos de quatro, o que possibilita seis combina&#x000e7;&#x000f5;es de sorteio (AABB; ABAB; ABBA; BABA; BAAB e BBAA). Assim, cada n&#x000fa;mero sorteado correspondeu a quatro crian&#x000e7;as. Esse m&#x000e9;todo apresenta duas vantagens: permite que, a cada quatro rec&#x000e9;m-nascidos que entram no estudo, haja sempre uma mesma quantidade de participantes submetidos ao tratamento A ou B; e dificulta a previs&#x000e3;o do tratamento a ser administrado para a pr&#x000f3;xima crian&#x000e7;a inclu&#x000ed;da no estudo, especialmente quando realizado separadamente para cada estrato. Foram sorteados, repetidamente, n&#x000fa;meros de um algarismo, at&#x000e9; se obter o tamanho amostral necess&#x000e1;rio para cada estrato.</p><p>O processo de randomiza&#x000e7;&#x000e3;o foi realizado pelos profissionais do Departamento de Epidemiologia da Faculdade de Sa&#x000fa;de P&#x000fa;blica da Universidade de S&#x000e3;o Paulo. O tratamento assinalado pela randomiza&#x000e7;&#x000e3;o foi anotado em um envelope opaco e lacrado. Para assegurar a n&#x000e3;o identifica&#x000e7;&#x000e3;o do surfactante usado em cada tratamento, a abertura do envelope, o preparo da medica&#x000e7;&#x000e3;o e a entrega do surfactante em seringa lacrada para equipe respons&#x000e1;vel diretamente pela administra&#x000e7;&#x000e3;o foi feita por pessoas n&#x000e3;o envolvidas no estudo (farmac&#x000ea;utico ou uma enfermeira de apoio). Todos os surfactantes foram estocados a uma temperatura de cerca de 4&#x000b0;C. Os m&#x000e9;dicos respons&#x000e1;veis pelos rec&#x000e9;m-nascidos permaneceram sem informa&#x000e7;&#x000e3;o em rela&#x000e7;&#x000e3;o ao tipo de surfactante utilizado em cada tratamento at&#x000e9; o final do estudo.</p></sec><sec><title>Estrat&#x000e9;gia de tratamento e controles ap&#x000f3;s o tratamento</title><p>Foi utilizada a dose de 100mg de fosfol&#x000ed;pides/kg para todos os rec&#x000e9;m-nascidos, em todos os tratamentos. Antes da administra&#x000e7;&#x000e3;o, os rec&#x000e9;m-nascidos foram aspirados apenas se necess&#x000e1;rio. Ap&#x000f3;s o tratamento, novas aspira&#x000e7;&#x000f5;es foram realizadas, respeitando-se um intervalo m&#x000ed;nimo de 1 hora entre a administra&#x000e7;&#x000e3;o e a aspira&#x000e7;&#x000e3;o, ou a qualquer momento se houvesse a hip&#x000f3;tese de obstru&#x000e7;&#x000e3;o da c&#x000e2;nula endotraqueal. O tratamento foi realizado se os rec&#x000e9;m-nascidos n&#x000e3;o apresentassem instabilidade fisiol&#x000f3;gica (presen&#x000e7;a de hipotens&#x000e3;o, bradicardia, convuls&#x000e3;o, pneumot&#x000f3;rax n&#x000e3;o resolvido ou pneumomediastino), com administra&#x000e7;&#x000e3;o em al&#x000ed;quota &#x000fa;nica, por c&#x000e2;nula orotraqueal, em velocidade constante, evitando-se refluxo da medica&#x000e7;&#x000e3;o. Em cada centro participante, os rec&#x000e9;m-nascidos dos dois grupos de estudo foram tratados de maneira id&#x000ea;ntica.</p><p>Cada rec&#x000e9;m-nascido poderia receber no m&#x000e1;ximo duas doses adicionais de surfactante, sendo que o crit&#x000e9;rio de retratamento foi estabelecido quando a rela&#x000e7;&#x000e3;o PaO<sub>2</sub>/FiO<sub>2</sub>fosse &#x02264;175, sem outra causa que explicasse a piora da fun&#x000e7;&#x000e3;o respirat&#x000f3;ria (por exemplo: pneumot&#x000f3;rax e hipertens&#x000e3;o pulmonar). O retratamento foi realizado ap&#x000f3;s um per&#x000ed;odo m&#x000ed;nimo de 6 horas da dose anterior e at&#x000e9; um limite m&#x000e1;ximo de 48 horas de vida, com igual dose e t&#x000e9;cnica de administra&#x000e7;&#x000e3;o.</p><p>Uma gasometria arterial foi coletada imediatamente antes e 1 e 6 horas ap&#x000f3;s a administra&#x000e7;&#x000e3;o da primeira dose do surfactante, para o c&#x000e1;lculo do &#x000ed;ndice de oxigena&#x000e7;&#x000e3;o (IO), por meio da f&#x000f3;rmula IO=(MAP x FiO<sub>2</sub>)/ PaO<sub>2</sub>x 100, sendo que MAP corresponde &#x000e0; press&#x000e3;o m&#x000e9;dia das vias a&#x000e9;reas. Os par&#x000e2;metros do ventilador foram anotados imediatamente antes e com 1, 6, 12, 18, 24, 30, 36, 42 e 48 horas ap&#x000f3;s o tratamento, para c&#x000e1;lculo os valores da MAP para cada grupo de estudo.</p></sec><sec><title>Defini&#x000e7;&#x000e3;o das vari&#x000e1;veis prim&#x000e1;rias</title><p>As vari&#x000e1;veis prim&#x000e1;rias para este estudo foram a mortalidade com 72 horas e com 28 dias de vida. As vari&#x000e1;veis secund&#x000e1;rias inclu&#x000ed;ram as complica&#x000e7;&#x000f5;es tipicamente associadas &#x000e0; prematuridade e &#x000e0; ventila&#x000e7;&#x000e3;o mec&#x000e2;nica.</p></sec><sec><title>An&#x000e1;lise estat&#x000ed;stica</title><p>As vari&#x000e1;veis cont&#x000ed;nuas foram analisadas pelo teste<italic>t</italic> de Student ou de Mann-Whitney, conforme o mais indicado. As vari&#x000e1;veis qualitativas foram analisadas pelo teste do &#x003c7;<sup>2</sup>ou exato de Fischer, conforme o mais apropriado. O c&#x000e1;lculo amostral para se detectar um aumento na mortalidade geral de 23,0% para 33,0%, conforme observado nas 41 maternidades brasileiras que participam do Projeto An&#x000e1;lise e Interven&#x000e7;&#x000e3;o para Melhoria do Cuidado Neonatal no Brasil, de 2009 a 2011, considerando-se um n&#x000ed;vel de signific&#x000e2;ncia de 0,05 e um poder de teste de 0,8, foi de 316 rec&#x000e9;m-nascidos. O n&#x000ed;vel de signific&#x000e2;ncia adotado foi um valor de p&#x02264;0,05. Foi utilizado para an&#x000e1;lise o <italic>software Stata &#x02013; Data Analysis and Statistical Software, vers&#x000e3;o 10.0 (StataCorp,</italic> Estados Unidos).</p></sec></sec><sec><title>RESULTADOS</title><p>Um total de 1.797 rec&#x000e9;m-nascidos de muito baixo peso foram admitidos no per&#x000ed;odo do estudo, dos quais 397 foram randomizado (<xref rid="f01002" ref-type="fig">Figura 1</xref>). Destes, 70 rec&#x000e9;m-nascidos foram exclu&#x000ed;dos. Dentre as causas das exclus&#x000f5;es, estiveram o n&#x000e3;o cumprimento de todos os crit&#x000e9;rios de inclus&#x000e3;o; o retratamento com mais de 48 horas de vida; rec&#x000e9;m-nascido randomizado, mas sem tratamento com surfactante; presen&#x000e7;a de corioamnionite; administra&#x000e7;&#x000e3;o de mais de tr&#x000ea;s doses de surfactante; a quebra de sigilo sobre o surfactante a ser administrado; o n&#x000e3;o seguimento da randomiza&#x000e7;&#x000e3;o do surfactante; o diagn&#x000f3;stico de malforma&#x000e7;&#x000e3;o maior; nascimento fora da institui&#x000e7;&#x000e3;o participante; centro cl&#x000ed;nico exclu&#x000ed;do do estudo; o preenchimento incompleto dos dados; a n&#x000e3;o obten&#x000e7;&#x000e3;o do Termo de Consentimento Livre e Esclarecido; aus&#x000ea;ncia de gasometria pr&#x000e9;-tratamento; rec&#x000e9;m-nascido com instabilidade hemodin&#x000e2;mica; dados registrados apenas a partir da segunda dose de surfactante; rec&#x000e9;m-nascido randomizado, por&#x000e9;m fora de ventila&#x000e7;&#x000e3;o mec&#x000e2;nica; e a falta de surfactante na institui&#x000e7;&#x000e3;o ap&#x000f3;s a administra&#x000e7;&#x000e3;o da segunda dose de surfactante. Dos 327 rec&#x000e9;m-nascidos restantes, 154 foram randomizados no Grupo Butantan e 173 no Grupo Controle (<xref rid="f01002" ref-type="fig">Figura 1</xref>). Os 1.400 rec&#x000e9;m-nascidos que n&#x000e3;o randomizados n&#x000e3;o preencheram todos os crit&#x000e9;rios de inclus&#x000e3;o. As principais caracter&#x000ed;sticas demogr&#x000e1;ficas peri e p&#x000f3;s-natais dos 327 rec&#x000e9;m-nascidos analisados s&#x000e3;o mostradas na
<xref rid="t1002" ref-type="table">tabela 1</xref>
. Os valores m&#x000e9;dios de peso de nascimento (990&#x000b1;245g <italic>versus</italic> 996&#x000b1;235g) e idade gestacional (28,0&#x000b1;2,1 semanas <italic>versus</italic> 28,1&#x000b1;2,2 semanas) foram similares para os Grupos Controle e Butantan, respectivamente. N&#x000e3;o foram observadas diferen&#x000e7;as em rela&#x000e7;&#x000e3;o ao sexo, ao uso de corticoide pr&#x000e9;-natal, &#x000e0; via de parto, &#x000e0; classifica&#x000e7;&#x000e3;o segundo o peso e a idade gestacional. Foram observados maiores valores do boletim de Apgar de 1 e de 5 minutos entre os rec&#x000e9;m-nascidos do Grupo Controle. Cerca de metade das crian&#x000e7;as randomizadas em ambos os grupos tiveram peso de nascimento entre 1.000 e 1.500g.</p><p><fig id="f01002" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Fluxograma da sele&#x000e7;&#x000e3;o dos pacientes</title></caption><graphic xlink:href="1679-4508-eins-12-4-0397-gf01-pt"/></fig></p><p>
<table-wrap id="t1002" orientation="portrait" position="float"><label>Tabela 1</label><caption><title>Caracter&#x000ed;sticas peri e p&#x000f3;s-natais dos 327 rec&#x000e9;m-nascidos analisados</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Caracter&#x000ed;sticas</th><th rowspan="1" colspan="1">Grupo Controle (n=173)</th><th rowspan="1" colspan="1">Grupo Butantan (n=154)</th><th rowspan="1" colspan="1">Valor de p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Peso de nascimento, g</td><td align="center" rowspan="1" colspan="1">990,65&#x000b1;245,70</td><td align="center" rowspan="1" colspan="1">996,01&#x000b1;235,84</td><td align="center" rowspan="1" colspan="1">0,84</td></tr><tr><td rowspan="1" colspan="1">Idade gestacional, semanas</td><td align="center" rowspan="1" colspan="1">28,03&#x000b1;2,07</td><td align="center" rowspan="1" colspan="1">28,14&#x000b1;2,16</td><td align="center" rowspan="1" colspan="1">0,64</td></tr><tr><td rowspan="1" colspan="1">Sexo, n (%)</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Masculino</td><td align="center" rowspan="1" colspan="1">86 (49,71)</td><td align="center" rowspan="1" colspan="1">84 (54,55)</td><td align="center" rowspan="1" colspan="1">0,38</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Feminino</td><td align="center" rowspan="1" colspan="1">87 (50,29)</td><td align="center" rowspan="1" colspan="1">70 (45,45)</td><td align="center" rowspan="1" colspan="1">0,38</td></tr><tr><td rowspan="1" colspan="1">Corticoide pr&#x000e9;-natal, n (%)</td><td align="center" rowspan="1" colspan="1">94 (54,34)</td><td align="center" rowspan="1" colspan="1">79 (51,30)</td><td align="center" rowspan="1" colspan="1">0,58</td></tr><tr><td rowspan="1" colspan="1">Parto vaginal, n (%)</td><td align="center" rowspan="1" colspan="1">66 (38,15)</td><td align="center" rowspan="1" colspan="1">61 (39,66)</td><td align="center" rowspan="1" colspan="1">0,79</td></tr><tr><td rowspan="1" colspan="1">Parto ces&#x000e1;reo, n (%)</td><td align="center" rowspan="1" colspan="1">107 (61,85)</td><td align="center" rowspan="1" colspan="1">93 (60,93)</td><td align="center" rowspan="1" colspan="1">0,79</td></tr><tr><td rowspan="1" colspan="1">Apgar 1&#x02019;</td><td align="center" rowspan="1" colspan="1">5,2&#x000b1;2,4</td><td align="center" rowspan="1" colspan="1">4,5&#x000b1;2,3</td><td align="center" rowspan="1" colspan="1">0,006</td></tr><tr><td rowspan="1" colspan="1">Apgar 5&#x02019;</td><td align="center" rowspan="1" colspan="1">7,9&#x000b1;1,5</td><td align="center" rowspan="1" colspan="1">7,4&#x000b1;1,7</td><td align="center" rowspan="1" colspan="1">0,02</td></tr><tr><td rowspan="1" colspan="1">AIG, n (%)</td><td align="center" rowspan="1" colspan="1">125 (72,25 )</td><td align="center" rowspan="1" colspan="1">121 (78,57)</td><td align="center" rowspan="1" colspan="1">0,19</td></tr><tr><td rowspan="1" colspan="1">PIG, n (%)</td><td align="center" rowspan="1" colspan="1">48 (27,75)</td><td align="center" rowspan="1" colspan="1">33 (21,43)</td><td align="center" rowspan="1" colspan="1">0,19</td></tr><tr><td rowspan="1" colspan="1">GIG, n (%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">PN &#x0003c;750g, n (%)</td><td align="center" rowspan="1" colspan="1">32 (18,5)</td><td align="center" rowspan="1" colspan="1">23 (14,9)</td><td align="center" rowspan="1" colspan="1">0,69</td></tr><tr><td rowspan="1" colspan="1">PN &#x02265;750g e &#x0003c;1.000g, n (%)</td><td align="center" rowspan="1" colspan="1">61 (35,26)</td><td align="center" rowspan="1" colspan="1">57 (37,01)</td><td align="center" rowspan="1" colspan="1">0,69</td></tr><tr><td rowspan="1" colspan="1">PN &#x02265;1.000g e &#x0003c;1.500g, n (%)</td><td align="center" rowspan="1" colspan="1">80 (46,24)</td><td align="center" rowspan="1" colspan="1">74 (48,05)</td><td align="center" rowspan="1" colspan="1">0,69</td></tr></tbody></table><table-wrap-foot><fn id="TFN1002"><p>Os resultados de PN, Apgar e idade gestacional s&#x000e3;o apresentados em m&#x000e9;dia &#x000b1; desvio padr&#x000e3;o. Vari&#x000e1;veis cont&#x000ed;nuas foram analisadas pelo teste
<italic>t</italic> de Student ou de Mann-Whitney, conforme o mais indicado. Vari&#x000e1;veis qualitativas analisadas pelo teste do &#x003c7;<sup>2</sup>ou exato de Fischer, conforme o mais apropriado. AIG: adequados para a idade gestacional; PIG: pequenos para a idade gestacional; GIG: grandes para a idade gestacional; PN: peso de nascimento.</p></fn></table-wrap-foot></table-wrap>
</p><p>Os rec&#x000e9;m-nascidos do Grupo Butantan necessitaram de mais doses de surfactante (m&#x000e9;dia &#x000b1; desvio padr&#x000e3;o) quando comparados aos do Grupo Controle (2,0&#x000b1;0,8<italic>versus</italic>1,5&#x000b1;0,7; p&#x0003c;0,001). N&#x000e3;o houve diferen&#x000e7;a em rela&#x000e7;&#x000e3;o ao momento (horas de vida) em que a primeira dose de surfactante foi administrada nos dois grupos analisados: Grupo Controle, com 5,35 horas (mediana), e Grupo Butantan, com 4,87 horas (mediana) (p=0,30).</p><sec><title>Desfechos prim&#x000e1;rios</title><p>N&#x000e3;o foram observadas diferen&#x000e7;as em rela&#x000e7;&#x000e3;o &#x000e0; mortalidade nos Grupos Butantan e Controle, tanto com 72 horas (14,19%<italic>versus</italic> 14,12%; p=0,98) como com 28 dias de vida (39,86%<italic>versus</italic> 33,33%; p=0,24). Tamb&#x000e9;m n&#x000e3;o foram observadas diferen&#x000e7;as em rela&#x000e7;&#x000e3;o &#x000e0; mortalidade em ambos os grupos quando analisadas por faixas de peso de nascimento, incluindo peso de nascimento &#x0003c;750g; peso de nascimento entre 750 e 999g, e peso de nascimento entre 1.000 e 1.499g (
<xref rid="t2002" ref-type="table">Tabelas 2</xref>
e
<xref rid="t3002" ref-type="table">3</xref>).</p><p>
<table-wrap id="t2002" orientation="portrait" position="float"><label>Tabela 2</label><caption><title>Mortalidade geral e por faixa de peso dentro das primeiras 72 horas ap&#x000f3;s a primeira dose de surfactante</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th style="font-weight:normal" align="left" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Grupo Controle n (%)</th><th rowspan="1" colspan="1">Grupo Butantan n (%)</th><th rowspan="1" colspan="1">Valor de p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mortalidade geral</td><td align="center" rowspan="1" colspan="1">24 (14,12)</td><td align="center" rowspan="1" colspan="1">22 (14,19 )</td><td align="center" rowspan="1" colspan="1">0,98</td></tr><tr><td rowspan="1" colspan="1">PN &#x0003c;750g (n=55)</td><td align="center" rowspan="1" colspan="1">11(35,48 )</td><td align="center" rowspan="1" colspan="1">10 (39,13 )</td><td align="center" rowspan="1" colspan="1">0,64</td></tr><tr><td rowspan="1" colspan="1">PN &#x02265;750g e &#x0003c;1.000g (n=115)</td><td align="center" rowspan="1" colspan="1">8 (13,56 )</td><td align="center" rowspan="1" colspan="1">8 (14,29 )</td><td align="center" rowspan="1" colspan="1">1,0</td></tr><tr><td rowspan="1" colspan="1">PN &#x02265;1000g e &#x0003c;1.500g (n=151)</td><td align="center" rowspan="1" colspan="1">5 (6,36 )</td><td align="center" rowspan="1" colspan="1">4 (5,48 )</td><td align="center" rowspan="1" colspan="1">1,0</td></tr></tbody></table><table-wrap-foot><fn id="TFN2002"><p>Vari&#x000e1;veis cont&#x000ed;nuas foram analisadas pelo teste
<italic>t</italic> de Student ou de Mann-Whitney, conforme o mais indicado. Vari&#x000e1;veis qualitativas analisadas pelo teste do &#x003c7;<sup>2</sup>ou exato de Fischer, conforme o mais apropriado. PN: peso de nascimento.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap id="t3002" orientation="portrait" position="float"><label>Tabela 3</label><caption><title>Mortalidade geral e por faixa de peso no 28
<underline>o</underline>
dia de vida</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Vari&#x000e1;veis secund&#x000e1;rias</th><th rowspan="1" colspan="1">Grupo Controle n (%)</th><th rowspan="1" colspan="1">Grupo Butantan n (%)</th><th rowspan="1" colspan="1">Valor de p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mortalidade geral</td><td align="center" rowspan="1" colspan="1">55 (33,33)</td><td align="center" rowspan="1" colspan="1">57 (39,86)</td><td align="center" rowspan="1" colspan="1">0,24</td></tr><tr><td rowspan="1" colspan="1">PN &#x0003c;750g (n=53)</td><td align="center" rowspan="1" colspan="1">21 (67,74)</td><td align="center" rowspan="1" colspan="1">15 (68,18)</td><td align="center" rowspan="1" colspan="1">0,97</td></tr><tr><td rowspan="1" colspan="1">PN &#x02265;750g e &#x0003c;1.000g (n=109)</td><td align="center" rowspan="1" colspan="1">23 (39,66)</td><td align="center" rowspan="1" colspan="1">26 (50,98)</td><td align="center" rowspan="1" colspan="1">0,24</td></tr><tr><td rowspan="1" colspan="1">PN &#x02265;1.000g e &#x0003c;1.500g (n=146)</td><td align="center" rowspan="1" colspan="1">11 (14,47)</td><td align="center" rowspan="1" colspan="1">16 (22,86)</td><td align="center" rowspan="1" colspan="1">0,19</td></tr></tbody></table><table-wrap-foot><fn id="TFN3002"><p>Vari&#x000e1;veis cont&#x000ed;nuas foram analisadas pelo teste
<italic>t</italic> de Student ou de Mann-Whitney, conforme o mais indicado. Vari&#x000e1;veis qualitativas analisadas pelo teste do &#x003c7;<sup>2</sup>ou exato de Fischer, conforme o mais apropriado. PN: peso de nascimento.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Desfechos secund&#x000e1;rios</title><p>N&#x000e3;o foram observadas diferen&#x000e7;as entre os rec&#x000e9;m-nascidos do Grupo Controle e os do Grupo Butantan em rela&#x000e7;&#x000e3;o &#x000e0;s vari&#x000e1;veis secund&#x000e1;rias analisadas no 28&#x000ba; dia de vida (<xref rid="t4002" ref-type="table">Tabela 4</xref>), com exce&#x000e7;&#x000e3;o de uma maior necessidade de crian&#x000e7;as em uso de oxig&#x000ea;nio no Grupo Butantan (45,28% <italic>versus</italic> 57,04%; p=0,05), uma maior frequ&#x000ea;ncia de diagn&#x000f3;stico de persist&#x000ea;ncia de canal arterial (31,45% <italic>versus</italic> 44,93%; p=0,02) e de enfisema pulmonar intersticial (7,64% <italic>versus</italic> 17,04%; p=0,01). A frequ&#x000ea;ncia de hemorragia pulmonar foi compar&#x000e1;vel em ambos os grupos (12,58% <italic>versus</italic> 11,59%; p=0,80).</p><p>
<table-wrap id="t4002" orientation="portrait" position="float"><label>Tabela 4</label><caption><title>Frequ&#x000ea;ncia das vari&#x000e1;veis secund&#x000e1;rias analisadas no 28
<underline>o</underline>
dia de vida</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Vari&#x000e1;veis secund&#x000e1;rias</th><th rowspan="1" colspan="1">Grupo Controle n (%)</th><th rowspan="1" colspan="1">Grupo Butantan n (%)</th><th rowspan="1" colspan="1">Valor de p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Uso de oxig&#x000ea;nio com 28 dias</td><td align="center" rowspan="1" colspan="1">72 (45,28)</td><td align="center" rowspan="1" colspan="1">77 (57,04)</td><td align="center" rowspan="1" colspan="1">0,05</td></tr><tr><td rowspan="1" colspan="1">Raios-x compat&#x000ed;vel com DBP</td><td align="center" rowspan="1" colspan="1">52 (65,00)</td><td align="center" rowspan="1" colspan="1">57 (72,15)</td><td align="center" rowspan="1" colspan="1">0,33</td></tr><tr><td rowspan="1" colspan="1">Hemorragia intracraniana (total)</td><td align="center" rowspan="1" colspan="1">39 (24,53)</td><td align="center" rowspan="1" colspan="1">43 (31,16)</td><td align="center" rowspan="1" colspan="1">0,20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grau I</td><td align="center" rowspan="1" colspan="1">17 (43,59)</td><td align="center" rowspan="1" colspan="1">17 (39,53)</td><td align="center" rowspan="1" colspan="1">0,94</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grau II</td><td align="center" rowspan="1" colspan="1">5 (12,82)</td><td align="center" rowspan="1" colspan="1">7 (16,28)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grau III</td><td align="center" rowspan="1" colspan="1">10 (25,64)</td><td align="center" rowspan="1" colspan="1">10 (23,26)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Grau IV</td><td align="center" rowspan="1" colspan="1">7 (17,95)</td><td align="center" rowspan="1" colspan="1">9 (20,93)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">PCA (n=297)</td><td align="center" rowspan="1" colspan="1">50 (31,45)</td><td align="center" rowspan="1" colspan="1">62 (44,93)</td><td align="center" rowspan="1" colspan="1">0,02</td></tr><tr><td rowspan="1" colspan="1">Sepse precoce (n=297)</td><td align="center" rowspan="1" colspan="1">58 (36,48)</td><td align="center" rowspan="1" colspan="1">50 (36,23)</td><td align="center" rowspan="1" colspan="1">0,97</td></tr><tr><td rowspan="1" colspan="1">Sepse tardia (n=293)</td><td align="center" rowspan="1" colspan="1">59 (37,58)</td><td align="center" rowspan="1" colspan="1">51 (37,50)</td><td align="center" rowspan="1" colspan="1">0,99</td></tr><tr><td rowspan="1" colspan="1">Hemorragia pulmonar (n=297)</td><td align="center" rowspan="1" colspan="1">20 (12,58)</td><td align="center" rowspan="1" colspan="1">16 (11,59)</td><td align="center" rowspan="1" colspan="1">0,80</td></tr><tr><td rowspan="1" colspan="1">Pneumot&#x000f3;rax (n=297)</td><td align="center" rowspan="1" colspan="1">13 (8,18)</td><td align="center" rowspan="1" colspan="1">12 (8,70)</td><td align="center" rowspan="1" colspan="1">0,87</td></tr><tr><td rowspan="1" colspan="1">Enfisema intersticial (n=292)</td><td align="center" rowspan="1" colspan="1">12 (7,64)</td><td align="center" rowspan="1" colspan="1">23(17,04)</td><td align="center" rowspan="1" colspan="1">0,01</td></tr><tr><td rowspan="1" colspan="1">Enterocolite necrosante (n=297)</td><td align="center" rowspan="1" colspan="1">11 (6,92)</td><td align="center" rowspan="1" colspan="1">11 (7,97)</td><td align="center" rowspan="1" colspan="1">0,83</td></tr><tr><td rowspan="1" colspan="1">Tempo de ventila&#x000e7;&#x000e3;o mec&#x000e2;nica (dias)</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0,06</td></tr><tr><td rowspan="1" colspan="1">Tempo total de oxigenioterapia (dias)</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">0,35</td></tr></tbody></table><table-wrap-foot><fn id="TFN4002"><p>Vari&#x000e1;veis cont&#x000ed;nuas foram analisadas pelo teste <italic>t</italic> de Student ou de Mann-Whitney, conforme o mais indicado. Vari&#x000e1;veis qualitativas analisadas pelo teste do &#x003c7;<sup>2</sup>ou exato de Fischer, conforme o mais apropriado. DBP: displasia broncopulmonar; PCA: persist&#x000ea;ncia do canal arterial.</p></fn></table-wrap-foot></table-wrap>
</p><p>Observou-se redu&#x000e7;&#x000e3;o tanto dos valores do IO (
<xref rid="t5002" ref-type="table">Tabela 5</xref>) como dos valores de MAP (
<xref rid="f02002" ref-type="fig">Figura 2</xref>) em ambos os grupos ap&#x000f3;s o tratamento com surfactante ex&#x000f3;geno, por&#x000e9;m a magnitude da queda foi mais importante nos rec&#x000e9;m-nascidos tratados com Survanta<sup>&#x000ae;</sup>ou Curosurf<sup>&#x000ae;</sup>, em rela&#x000e7;&#x000e3;o aos tratados com surfactante Butantan.</p><p>
<table-wrap id="t5002" orientation="portrait" position="float"><label>Tabela 5</label><caption><title>Valores de &#x000ed;ndice de oxigena&#x000e7;&#x000e3;o antes do tratamento e 1 e 6 horas depois (valores em percentis)</title></caption><table frame="hsides" rules="groups"><colgroup width="8%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Percentil</th><th rowspan="2" colspan="1">Valor de p</th><th colspan="2" style="font-weight:normal" rowspan="1">10
<hr/></th><th colspan="2" style="font-weight:normal" rowspan="1">25
<hr/></th><th colspan="2" style="font-weight:normal" rowspan="1">50
<hr/></th><th colspan="2" style="font-weight:normal" rowspan="1">75
<hr/></th><th colspan="2" style="font-weight:normal" rowspan="1">90
<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Grupo</th><th rowspan="1" colspan="1">GC</th><th rowspan="1" colspan="1">GB</th><th rowspan="1" colspan="1">GC</th><th rowspan="1" colspan="1">GB</th><th rowspan="1" colspan="1">GC</th><th rowspan="1" colspan="1">GB</th><th rowspan="1" colspan="1">GC</th><th rowspan="1" colspan="1">GB</th><th rowspan="1" colspan="1">GC</th><th rowspan="1" colspan="1">GB</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Pr&#x000e9; tratamento</td><td align="center" rowspan="1" colspan="1">0,92</td><td align="center" rowspan="1" colspan="1">5,4</td><td align="center" rowspan="1" colspan="1">5,4</td><td align="center" rowspan="1" colspan="1">7,2</td><td align="center" rowspan="1" colspan="1">6,7</td><td align="center" rowspan="1" colspan="1">10,7</td><td align="center" rowspan="1" colspan="1">10,9</td><td align="center" rowspan="1" colspan="1">16,2</td><td align="center" rowspan="1" colspan="1">17,3</td><td align="center" rowspan="1" colspan="1">24,5</td><td align="center" rowspan="1" colspan="1">25,6</td></tr><tr><td rowspan="1" colspan="1">1 hora ap&#x000f3;s</td><td align="center" rowspan="1" colspan="1">&#x0003c;0,001</td><td align="center" rowspan="1" colspan="1">2,4</td><td align="center" rowspan="1" colspan="1">2,7</td><td align="center" rowspan="1" colspan="1">3,0</td><td align="center" rowspan="1" colspan="1">4,6</td><td align="center" rowspan="1" colspan="1">4,6</td><td align="center" rowspan="1" colspan="1">7,8</td><td align="center" rowspan="1" colspan="1">7,2</td><td align="center" rowspan="1" colspan="1">12,7</td><td align="center" rowspan="1" colspan="1">13,2</td><td align="center" rowspan="1" colspan="1">20,1</td></tr><tr><td rowspan="1" colspan="1">6 horas ap&#x000f3;s</td><td align="center" rowspan="1" colspan="1">&#x0003c;0,001</td><td align="center" rowspan="1" colspan="1">2,0</td><td align="center" rowspan="1" colspan="1">2,3</td><td align="center" rowspan="1" colspan="1">2,6</td><td align="center" rowspan="1" colspan="1">4,0</td><td align="center" rowspan="1" colspan="1">4,0</td><td align="center" rowspan="1" colspan="1">6,8</td><td align="center" rowspan="1" colspan="1">6,4</td><td align="center" rowspan="1" colspan="1">10,1</td><td align="center" rowspan="1" colspan="1">12,0</td><td align="center" rowspan="1" colspan="1">19,3</td></tr></tbody></table><table-wrap-foot><fn id="TFN5002"><p>Vari&#x000e1;veis cont&#x000ed;nuas foram analisadas pelo teste
<italic>t</italic> de Student ou de Mann-Whitney, conforme o mais indicado. Vari&#x000e1;veis qualitativas analisadas pelo teste do &#x003c7;<sup>2</sup>ou exato de Fischer, conforme o mais apropriado. GC: Grupo Controle; GB: Grupo Butantan. Valores em percentis.</p></fn></table-wrap-foot></table-wrap>
</p><p><fig id="f02002" orientation="portrait" position="float"><label>Figura 2</label><caption><title>Valores da press&#x000e3;o m&#x000e9;dia de vias a&#x000e9;reas, antes e ap&#x000f3;s o tratamento, em ambos grupos de estudo</title></caption><graphic xlink:href="1679-4508-eins-12-4-0397-gf02-pt"/></fig></p><p>Em rela&#x000e7;&#x000e3;o &#x000e0;s complica&#x000e7;&#x000f5;es observadas durante a administra&#x000e7;&#x000e3;o do surfactante, observou-se que menos crian&#x000e7;as do Grupo Butantan apresentaram bradicardia em rela&#x000e7;&#x000e3;o ao Grupo Controle (8,3%<italic>versu</italic> s 36,7%; p=0,002) tendo ambos os grupos apresentado similar incid&#x000ea;ncia de refluxo de surfactante pela c&#x000e2;nula traqueal (83,3%<italic>versus</italic> 76,7%; p=0,470).</p></sec></sec><sec><title>DISCUSS&#x000c3;O</title><p>Este estudo multic&#x000ea;ntrico teve como objetivo principal verificar a efic&#x000e1;cia e a seguran&#x000e7;a do novo surfactante produzido pelo Instituto Butantan em rela&#x000e7;&#x000e3;o aos produtos comercialmente dispon&#x000ed;veis no Brasil. A mortalidade encontrada tanto com 72 horas de vida como no 28&#x000ba; dia de vida foi similar &#x000e0; observada com o uso dos dois surfactantes de origem animal utilizados no nosso meio. Essas observa&#x000e7;&#x000f5;es demonstram que o principal benef&#x000ed;cio do uso de surfactante ex&#x000f3;geno para o tratamento de rec&#x000e9;m-nascidos com SDR, ou seja, a redu&#x000e7;&#x000e3;o da mortalidade, foi atingido. Esse achado tem sua import&#x000e2;ncia bem estabelecida quando lembramos que, em v&#x000e1;rias maternidades p&#x000fa;blicas de nosso pa&#x000ed;s, o surfactante ex&#x000f3;geno n&#x000e3;o est&#x000e1; dispon&#x000ed;vel para uso cl&#x000ed;nico de rotina, em decorr&#x000ea;ncia de seu elevado custo. De igual import&#x000e2;ncia &#x000e9; o achado, em ambos grupos de estudo, de uma similar taxa de ocorr&#x000ea;ncia das principais doen&#x000e7;as relacionadas &#x000e0; prematuridade, incluindo a displasia broncopulmonar, a hemorragia intracraniana graus III e IV, e a enterocolite necrosante. Embora o Grupo Butantan tenha apresentado um menor boletim de Apgar de 5 minutos (7,9&#x000b1;1,5<italic>versus</italic>7,4&#x000b1;1,7; p=0,006), a magnitude da diferen&#x000e7;a n&#x000e3;o teve significado cl&#x000ed;nico.</p><p>Embora a incid&#x000ea;ncia de pneumot&#x000f3;rax tenha sido muito parecida nos dois grupos de estudo, as crian&#x000e7;as tratadas com surfactante Butantan apresentaram uma maior incid&#x000ea;ncia de enfisema intersticial pulmonar. Ambos os grupos apresentam uma incid&#x000ea;ncia geral de ocorr&#x000ea;ncia de ar extrapulmonar bem maior que a observada, tanto com o uso do lucinactante (um surfactante sint&#x000e9;tico aguardando aprova&#x000e7;&#x000e3;o do<italic>Food and Drug Administration</italic>&#x02212; FDA) com o do poractante alfa (9,2% e 7,3%, respectivamente).<sup>(<xref rid="B13" ref-type="bibr">13</xref>)</sup>A resposta imediata &#x000e0; terap&#x000ea;utica com surfactante foi mais evidente no Grupo Controle, sendo avaliada por uma redu&#x000e7;&#x000e3;o mais acentuada da press&#x000e3;o m&#x000e9;dia de vias a&#x000e9;reas ap&#x000f3;s o tratamento e com melhores valores de IO. No entanto, quando se analisa a varia&#x000e7;&#x000e3;o desses par&#x000e2;metros nos dois grupos estudados, constata-se que n&#x000e3;o foram associados a diferen&#x000e7;as cl&#x000ed;nicas entre eles, fato demonstrado pela semelhan&#x000e7;a nos tempos de ventila&#x000e7;&#x000e3;o mec&#x000e2;nica, tempo total de oxig&#x000ea;nio e necessidade de oxig&#x000ea;nio com 28 dias de vida, al&#x000e9;m da similar taxa de mortalidade com 72 horas e no 28&#x000ba; dia de vida, na incid&#x000ea;ncia de hemorragia pulmonar e de pneumot&#x000f3;rax.</p><p>A literatura internacional discute h&#x000e1; cerca de duas d&#x000e9;cadas sobre a melhor forma de avaliar se um surfactante funciona adequadamente e como a efic&#x000e1;cia entre dois surfactantes poderia ser comparada no tratamento de uma determinada doen&#x000e7;a respirat&#x000f3;ria. Com base em evid&#x000ea;ncias publicadas, admite-se que os efeitos agudos do surfactante sobre os pulm&#x000f5;es (avalia&#x000e7;&#x000e3;o da oxigena&#x000e7;&#x000e3;o) n&#x000e3;o predizem sua efic&#x000e1;cia com clareza e s&#x000e3;o menos importantes do que a avalia&#x000e7;&#x000e3;o de sua influ&#x000ea;ncia na mortalidade associada &#x000e0; insufici&#x000ea;ncia respirat&#x000f3;ria.<sup>(<xref rid="B14" ref-type="bibr">14</xref>-<xref rid="B17" ref-type="bibr">17</xref>)</sup>A primeira grande evid&#x000ea;ncia desse fato est&#x000e1; nos estudos que compararam os surfactantes de origem animal aos sint&#x000e9;ticos, em que fica claro que o surfactante utilizado para o tratamento melhora de fun&#x000e7;&#x000e3;o ap&#x000f3;s sua exposi&#x000e7;&#x000e3;o ao pulm&#x000e3;o prematuro e sua modifica&#x000e7;&#x000e3;o dentro do pneum&#x000f3;cito II, com posterior libera&#x000e7;&#x000e3;o para o alv&#x000e9;olo.<sup>(<xref rid="B14" ref-type="bibr">14</xref>)</sup>Assim, a avalia&#x000e7;&#x000e3;o da mortalidade associada &#x000e0; insufici&#x000ea;ncia respirat&#x000f3;ria apresenta-se como o par&#x000e2;metro mais importante na avalia&#x000e7;&#x000e3;o da efic&#x000e1;cia da terap&#x000ea;utica com surfactante, quando comparada com a avalia&#x000e7;&#x000e3;o da oxigena&#x000e7;&#x000e3;o propriamente dita. A segunda grande evid&#x000ea;ncia &#x000e9; mostrada com o uso de surfactante ex&#x000f3;geno no tratamento da s&#x000ed;ndrome de aspira&#x000e7;&#x000e3;o meconial em rec&#x000e9;m-nascidos.<sup>(<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>)</sup>Nessa doen&#x000e7;a, a literatura internacional mostra que o tratamento com surfactante ex&#x000f3;geno melhora a oxigena&#x000e7;&#x000e3;o a curto prazo. No entanto, apesar dessa melhora na oxigena&#x000e7;&#x000e3;o, estudos cl&#x000ed;nicos n&#x000e3;o confirmaram a redu&#x000e7;&#x000e3;o da mortalidade na s&#x000ed;ndrome de aspira&#x000e7;&#x000e3;o meconial com a terap&#x000ea;utica com surfactante ex&#x000f3;geno, fato este que torna o uso do surfactante, nessa doen&#x000e7;a, objeto de controv&#x000e9;rsia e sem consenso.<sup>(<xref rid="B20" ref-type="bibr">20</xref>)</sup>Isso refor&#x000e7;a a superioridade da avalia&#x000e7;&#x000e3;o da mortalidade na an&#x000e1;lise da efic&#x000e1;cia da terap&#x000ea;utica com surfactante, em rela&#x000e7;&#x000e3;o aos seus efeitos sobre a oxigena&#x000e7;&#x000e3;o.</p><p>Al&#x000e9;m da an&#x000e1;lise da efic&#x000e1;cia, tamb&#x000e9;m se faz necess&#x000e1;rio avaliar a seguran&#x000e7;a desse novo medicamento a curto (no momento da administra&#x000e7;&#x000e3;o) e a longo prazo (eventos que podem ocorrer como resultado de seu uso). Neste estudo, analisou-se a seguran&#x000e7;a de ambos os grupos no momento da sua administra&#x000e7;&#x000e3;o (bradicardia e refluxo de surfactante pela c&#x000e2;nula orotraqueal) e quanto &#x000e0; ocorr&#x000ea;ncia de poss&#x000ed;veis efeitos adversos associados aos mesmos. Os resultados obtidos mostraram que, durante a administra&#x000e7;&#x000e3;o do surfactante, houve uma maior incid&#x000ea;ncia de refluxo do surfactante pela c&#x000e2;nula orotraqueal, entre os rec&#x000e9;m-nascidos do Grupo Butantan, e de bradicardia ap&#x000f3;s a administra&#x000e7;&#x000e3;o do surfactante, entre os rec&#x000e9;m-nascidos do Grupo Controle. Com rela&#x000e7;&#x000e3;o aos efeitos adversos associados ao uso do surfactante, destaca-se a ocorr&#x000ea;ncia de hemorragia pulmonar descrita na literatura internacional como o evento mais grave associado a esse tratamento.<sup>(<xref rid="B21" ref-type="bibr">21</xref>)</sup>Os resultados obtidos neste estudo mostraram que a hemorragia pulmonar ocorreu de forma semelhante nos dois grupos analisados.</p><p>Em rela&#x000e7;&#x000e3;o &#x000e0; dose de surfactante utilizada neste estudo, um certo n&#x000fa;mero de estudos cl&#x000ed;nicos e farmacocin&#x000e9;ticos indica que doses maiores s&#x000e3;o mais eficazes.<sup>(<xref rid="B22" ref-type="bibr">22</xref>)</sup>A op&#x000e7;&#x000e3;o do uso da dose de 100 mg/kg foi baseada no fato de que, na SDR, inibidores da prote&#x000ed;na derivada de soro e mediadores inflamat&#x000f3;rios que inativam o sistema de surfactante se acumulam progressivamente, e o tratamento realizado na sua fase inicial &#x000e9; efetivo com a dose de 100mg/kg.<sup>(<xref rid="B23" ref-type="bibr">23</xref>)</sup></p><p>V&#x000e1;rios estudos comparando surfactantes sint&#x000e9;ticos (sem prote&#x000ed;nas em sua composi&#x000e7;&#x000e3;o) e naturais (de origem tanto bovina como porcina) foram realizados, com resultados melhores entre os de origem animal em rela&#x000e7;&#x000e3;o aos sint&#x000e9;ticos. De modo semelhante aos resultados do presente estudo, as compara&#x000e7;&#x000f5;es entre diferentes surfactantes de origem animal (com as apoprote&#x000ed;nas B e C em sua composi&#x000e7;&#x000e3;o) n&#x000e3;o apresentaram resultados diferentes em rela&#x000e7;&#x000e3;o &#x000e0; mortalidade e &#x000e0;s principais morbidades relacionadas &#x000e0; prematuridade, incluindo par&#x000e2;metros de ventila&#x000e7;&#x000e3;o mec&#x000e2;nica, incid&#x000ea;ncia de pneumot&#x000f3;rax, enfisema intersticial, hemorragia intracraniana e persist&#x000ea;ncia de canal arterial, quando comparados na mesma dose de tratamento.<sup>(<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>)</sup></p></sec><sec><title>CONCLUS&#x000c3;O</title><p>O novo surfactante desenvolvido para o tratamento da s&#x000ed;ndrome do desconforto respirat&#x000f3;rio em rec&#x000e9;m-nascidos &#x000e9; eficaz e seguro, o que foi demonstrado por uma similar mortalidade neonatal e por uma compar&#x000e1;vel ocorr&#x000ea;ncia de hemorragia pulmonar e de pneumot&#x000f3;rax em ambos grupos de estudo.</p></sec></body><back><fn-group><fn fn-type="supplementary-material"><p><bold>Registro na Base de Ensaios Cl&#x000ed;nicos</bold>(
<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>
): protocolo identifica&#x000e7;&#x000e3;o: NCT02305160</p></fn></fn-group></back></sub-article></article>